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BACKGROUND AND AIM 
The immune system is a complex integrated network of chemical and cellular 
mediators that developed during evolution to defend the body from any form of 
chemical, traumatic or infective insult to their integrity.  
A proper immune response relies on the innate immunity, that is responsible for a 
first line of defense against aggression and the aspecific recognition of a limited 
repertoire of antigens, and, later, on the adaptative immunity which includes 
chemical and cellular mediators responsible for a more powerful and specific 
defensive response from any form of antigen. Alterations of any part of the immune 
response results in failure of host defense and, in particular, of immunodeficiency, 
autoimmunity and cancer predisposition.  
Recent evidence highlights that the skin participates in a host defenses either 
acting as a primary boundary for germs, as the principal site of environment–host 
interactions, or directly in the developmental process of the immune system. As a 
matter of fact, skin and skin annexa abnormalities, such as skin dryness, brittleness 
of hair, nail abnormalities and abnormal dentition, can be not infrequently associated 
with distinct forms of immunodeficiency and may be a warning sign of 
immunodeficiency, since both epidermal and thymic epithelium have ectodermal 
origin. 
Severe combined immunodeficiency diseases (SCIDs) represent a 
heterogeneous group of rare genetic syndromes responsible for severe dysfunctions 
of the immune system, which share similar clinical manifestations. SCID is the most 
severe form of inherited primary immunodeficiency (PID) and its prevalence is 
approximately 1:100,000 live births, with a higher prevalence in males (1). SCIDs 
are difficult to recognize clinically because so many different infectious scenarios 
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can occur. Without a functional cellular and humoral immune system SCID patients 
are susceptible to recurrent infections such as severe bacterial, viral, or fungal 
infections early in life and often present with interstitial lung disease, chronic 
diarrhea, and failure to thrive. In addition, some patients develop skin rashes, usually 
caused by maternal T cells transplacental engraftment during fetal life or by a wide 
autoreaction due to the activation of autologous T cells against skin components (2, 
3). 
Patients affected with particular forms of PID show anincreased susceptibility to 
cancer. In particular, a high cancer susceptibility has beenreported for a rare form of 
PID calledAtaxia Telangiectasia (A-T) whose clinical hallmark is represented by the 
cerebellar neurodegeneration with the loss of Purkinje cells.  Recently, in a few 
clinical trialsit has been documented that a short-term treatment with glucocorticoids 
(GCs) is able to partially rescue either the A-T neurological phenotype and 
lymphocytes proliferation, even though the mechanism of action has not yet been 
defined (4-7).  
Conventionally, SCIDs have been so far classified, on the basis of the 
involvement of different cell lines in the pathogenesis of the disease and of the 
subsequent different clinical immunological phenotypes related to a specific genetic 
defect. T cell–deficient but normal B cell (T−B+) SCID and bothT cell– and B cell–
deficient (T−B−) SCID, in the presence or absence of NK cells (8). This 
classification helps in directing molecular studies toward a certain genetic alteration, 
since it  is representative of the stage where the blockage occurs during the 
differentiation process. 
More recently, advances in next generation DNA sequencing allowed new 
gene identification through whole exome or whole genome sequencing (WES, WGS) 
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of several forms of PIDs of unknown causes making the genetic identification of 
immunodeficiency syndromes more efficient (9). Only in the last two years, using 
this technology 34 new gene defects have been identified.Most of these 
immunodeficiencies are rare, even though some of them occur more frequently than 
what previously reported,as documented by several groups (10). Based on the 
principle of massively parallel sequencing, NGS technology provides an advanced 
tool to dramatically increase the speed at which DNA can be sequenced at a lower 
cost as compared to the traditional Sanger sequencing approach. 
In this context my PhD program has been focused on the study of some 
immunological disorders, in order to identify new scenarios in pathogenesis, 
diagnosis and therapeutic approaches. 
This thesis reports the results obtained during my PhD course in “Human 
Reproduction, Development and Growth” (XXVIII Cycle) from 2013 to 2016. 
During these years my research has been focused on the study of the following lines 
of research: 
 role of the autophagy pathway in the pathogenesis of Ataxia 
Telangiectasiaand the potential positive effect of glucocorticoids on 
the rescue of a proper cell clearance process in lymphocytes of the 
patients affected with this disease; 
 role of the common gamma chian (γc) in cell cycle progression and 
survival of continuous primary human malignant cell lines; 
 thymic stromal alterations responsible for immunological disorders; 
 application of Next Generation Sequencing technique for the 
diagnosis of immunodeficiencies.  
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CHAPTER I 
Ataxia-Telangiectasia 
Ataxia Telangiectasia (A-T) (http://omim.org/entry/208900) is a rare genetic 
disorder of childhood due to mutations in the Ataxia Telangiectasia Mutated (ATM) 
gene. To date, over 600 distinct ATM mutations have been reported 
(www.hgmd.cf.ac.uk/ac/gene.php?gene=ATM). Different types of ATM gene 
mutations are associated to different forms of the disease. Truncating mutations 
cause the classic form of A-T associated to the complete absence of the protein 
function.  Splice site mutations or missense mutations with expression of the protein 
at some extent, thus exerting residual kinase activity, are responsible for milder 
forms of A-T (11).   
ATM exerts a central role in the signal-transduction pathway activated by 
DNA double strand breaks (DSBs), and, therefore, A-T is considered the prototype 
of the DNA-repair defect syndromes. In response to DSB formation, cell cycle arrest 
and DNA repair occur by the activation of nuclear form of ATM and several DNA-
repair and cell cycle checkpoint proteins (12). Defects in DSBs repaircould also 
account for the high incidence of chromosomal rearrangements involving the sites of 
the immune system genes.  Of note, gene rearrangements and DSBs repair by ATM 
are required for a proper immune cell maturation. ATM deficiency may affect VDJ 
recombination but poorly lymphocyte development. In B cells, the absence of a 
functional ATM leads to a defect in class switch recombination (CSR), thus 
supporting a role of ATM in this process (13). 
There is also evidence in favor of an extranuclear role for ATM, not involving 
the DNA damage repair process (14). In ATM-deficient cells, the absence of 
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cytosolic functional ATM leads to a reduced internalization of phytohaemagglutinin 
(PHA), depolarization in response to extracellular K
+
, defective Ca2
+
 mobilization, a 
decrease in the duration of Ca2
+
 and Na
+
 firing and defective signaling (15). In the 
cytoplasm, ATM exists as a soluble protein or inside subcellular organelles, such as 
peroxisomes, important for β-oxidation of fatty acids and detoxification, and 
endosomes, involved in endocytosis and intracellular routing of receptors and other 
molecules.  Possible targets of cytosolic ATM are the 4EBP1 protein (15), and other 
molecules involved in oxidative metabolism or in cell protection from the metabolic 
stress (14). 
The clinical phenotype consists of oculocutaneous teleangiectasia, 
immunodeficiency, high incidence of neoplasms and hypersensitivity to ionizing 
radiations. The hallmarks of the disease are related to the progressive neurological 
degeneration, with a selective depletion of Purkinje cells, which greatly impairs the 
quality of life, invariably confining the patients to wheelchair (16, 17). Together with 
the neurological degeneration, A-T patients show immunodeficiency, usually 
affecting both humoral and cellular responses, even though severe infections are not 
frequent in these patients.  Infections in these patients mainly involve the respiratory 
tract and seem to be related to the neurological alterations themselves rather than to 
the immune defect (18). The prognosis for survival is poor. To date, A-T remains an 
incurable disease that leads relentlessly to death around the third decade of life 
predominantly for progressive neurodegeneration, pulmonary failure with or without 
identifiable pneumonia, and cancer  (12, 19).  
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1.1 Evaluation of the potential role of autophagy in the pathogenesis of Ataxia 
Telangiectasia 
Ataxia-Telangiectasia clinical hallmark is represented by the cerebellar 
neurodegeneration with the loss of Purkinje cells (20).  Recently, in a few clinical 
trialsit has been documented that a short-term treatment with glucocorticoids (GCs) 
is able to partially rescue the A-T neurological phenotype and lymphocytes 
proliferation even though the mechanism of action has not yet been defined (4-7).  
Evidence exists that ATM exerts additional functions in the cytoplasm 
independent of its role in the DNA damage response (21), such as participation to the 
autophagy pathway (22). To date, many studies have been performed to identify the 
pathogenic mechanism responsible for the disease, mainly focusing on the nuclear 
activity of ATM protein. Thus, the pleiotropic aspects of the phenotype have only 
partially been clarified.  
Autophagy alterations have been implicated in several chronic nervous 
system disorders, such as proteinopathies (Alzheimer’s, Parkinson’s, Huntington’s 
diseases) and acute brain injuries (23), whose hallmarks are organelle damage, 
synaptic dysfunction and neuronal degeneration. Autophagy, known originally as an 
adaptive response to nutrient deprivation in mitotic cells, including lymphocytes, is 
now recognized as an arbiter of neuronal survival and homeostasis in that neurons 
are post-mitotic cells, which require effective protein degradation to prevent 
accumulation of toxic aggregates. Reactive oxygen species (ROS) generation from 
dysfunctional mitochondria, as documented in cells from A-T patients, is a potent 
trigger of autophagy, which acts to clean up damaged organelles (24). It has been 
demonstrated that in the presence of elevated ROS levels, the activation of the 
serin/threonine kinase ATM in the cytoplasm leads to activation of LKB1 tumor 
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suppressor gene, which, in turn, phosphorylates and activates AMP protein kinase 
(AMPK) (25). AMPK regulates several metabolic processes and activates Tuberous 
sclerosis complex 2 (TSC2), which participates in energy sensing and growth factor 
signaling (26). TSC2, by inhibiting the GTPase Rheb, is able to repress mTOR 
kinase, a key regulator of the protein synthesis and cell growth, thus leading to the 
activation of autophagy (27). The repression of mTOR complex 1 (mTORC1) 
signaling results in the absence of phosphorylation of p70 ribosome S6 kinase 
(p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1), direct 
targets of the mTOR kinase, involved in protein synthesis and survival. 
Thus, a direct effect of ATM-mediated inhibition of mTORC1 is the 
activation of autophagy, a dynamic process, which includes the initiation, formation, 
maturation and degradation of autophagosomes (APs). The lipidation of LC3 
molecule, through the conjugation of phosphatidylethanolamine (PE) converting the 
cytosolic LC3 (LC3-I) to the autophagic vesicle-associated form (LC3-II), is 
essential for autophagy induction, and thus for APs visualization by transmission 
electronic microscopy (TEM). The lipidated LC3-II form may also be visualized 
under fluorescence microscope in that it shows a punctate staining pattern and by 
western blot in that it has faster electrophoretic mobility compared with diffused 
LC3-I form (28). An increase of LC3-II form may result from either an enhancement 
of APs biogenesis or inhibition of APs degradation, or may be due by other 
mechanisms (28). p62/sequestosome (SQSTM1), is a further biomarker widely used 
to evaluate the appropriateness of autophagic activity. It can bind LC3 protein to 
promote the recruitment of unwanted material into autophagosomes and the 
subsequent degradation through autolysosomes. When a normal autophagic flux 
occurs, p62, as substrate of autophagy itself, is degraded (29). Thus, increased LC3-
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II and decreased SQSTM1 levels are indicative of an appropriate autophagic activity 
whereas increased SQSTM1 levels, reveal defective autophagy (29). 
Recently, genes involved in autophagosomal/lysosomal biogenesis and 
lysosomal functionality, belonging to the Coordinated Lysosomal Expression and 
Regulation (CLEAR) network, have been described as crucial for a proper cell 
clearance through autophagic process (30) during catabolic conditions. In particular, 
the expression of the UVRAG (UV Radiation Resistance Associated) gene plays a 
pivotal role in the first phase of the process, which consists in the APs biogenesis and 
formation (31, 32). To ensure a proper degradation of unwanted material and thus 
cell clearance, the APs must fuse to the lysosomes that contain several active 
hydrolases, such as β-glucosidase, β-glucuronidaseand cathepsins (30). The fusion 
process depends on the intracellular positioning of lysosomes in that, only the 
lysosomes that are transported along microtubules in the perinuclear area, thanks to 
kinesins (such as KIF2A and KIF1B-β and the monomeric GTPase ARL8B), are able 
to fuse with APs (33). Moreover, Vps11 and Vps18 (Vacuolar Protein Sorting 11 and 
18) proteins products are also involved in vesicular trafficking to allow the encounter 
between APs and lysosomes, resulting in their fusion (34). Eventually, the formation 
of autolysosomes (ALs), whose content is degraded by lysosomal enzymes and 
recycled, leads to preserve cellular homeostasis. 
In the present work, we evaluated whether abnormal autophagy may be 
involved in the pathogenesis of A-T by analyzing the autophagic vesicles and the 
genes implicated in the different stages of autophagy process.  
To address the involvement of abnormal autophagic process in the 
pathogenesis of A-T, we first analyzed, under TEM, the lymphocytes isolated from 
A-T patients or healthy controls maintained in normal culture conditions or in a 
 
 12 
serum-starved condition, which is a classical pro-autophagic stimulus. Ultrastructural 
analysis of healthy control lymphocytes by TEM showed the morphological aspects 
of a cell in unstarved culture conditions (Figure 1A) and the accumulation of 
autophagic vesicles (AVs) at different maturation stages (i.e. autophagosomes and 
autolysosomes) in a cell after serum starvation for 2h (Figure 1B). Ultrastructural 
analysis of A-T patient lymphocytes at basal conditions revealed a general increase 
in AV size and number (Figure 1C-F), not observed in healthy control cells. In the 
Figure 1D, autophagosomal vesicles with a double-membrane profile in the process 
of engulfment of targeted organelles in A-T lymphocytes are shown. In the Figure 
1E, ALs containing degraded material and, in the Figure 1F, vacuolar structures in 
the late stage of the autophagolysosomal pathway are shown.   
 Next we analyzed distinct types of AVs, such as autophagosomes and 
autolysosomes. TEM revealed that A-T patients exhibit higher number of APs and 
decrease in ALs, as compared to healthy subjects (mean: 13.60 vs 2.30/100 µm
2
; p = 
0.03; mean: 2.10 vs 4.7/100 µm
2
 respectively) (Figure 1G). This suggests that fusion 
of APs to lysosomes and, thus, their conversion to autolysosomes, could be impaired 
in A-T. A further quantitative analysis of ALs revealed that, in the A-T patients, they 
were not detected in the majority of the fields analyzed, differently from the controls 
(83 vs 36% ALs
- 
fields, respectively) (Figure 1H), resulting in an APs/ALs ratio 
much higher in the patients than in the controls (12.22 vs 0.93; p = 0.03) (Figure 1I). 
Indeed, the APs number did not further increase under starvation in patient cells, 
indicating that in A-T an inhibition of autophagy flux rather than a stimulation of 
APs biogenesis occurs (Figure 1J). 
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FIGURE 1. Lymphocytes from patients affected with A-T show accumulation of autophagosomes. 
A-B, Electron micrographs of freshly isolated lymphocytes from healthy controls in unstarved culture 
conditions or after serum starvation for 2 h showing the accumulation of autophagic vesicles (AVs).  
Scale bar: 500 nm. C-F, Electron micrographs of lymphocytes isolated from A-T patients at basal 
conditions showing a general engulfment of AVs. D, Autophagosomal vesicles (black arrows) with a 
double-membrane profile in the process of engulfment of targeted organelles. E, Autolysosomes 
(ALs) (white arrows) containing degraded material. F, Vacuolar structures in the late stage of the 
autophagolysosomal pathway. Scale bar: 1 μm. G, Number of autophagic vesicles/100 μm2 in freshly 
isolated lymphocytes from healthy controls and A-T patients. P = 0.03. H, Percentage of ALs
-
 fields 
in fresh isolated lymphocytes from healthy controls and A-T patients. I, APs/ALs ratio for freshly 
isolated lymphocytesfrom healthy controls and A-T patients. P< 0.05. J, Number of 
autophagosomes/100 μm2 in freshly isolated lymphocytes from healthy controls and A-T patients at 
basal conditions and after serum starvation for 2h. All data are expressed as mean ± S.D. 
 
To further confirm that in A-T patients the autophagy was present at basal 
conditions, we tested the presence of LC3 puncta in lymphocytes from both A-T 
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patients and controls. Immunofluorescence analysis documented the presence of LC3 
puncta in A-T patients but not in the controls, who showed a diffuse staining pattern 
of LC3 (Figure 2A).  Moreover, as shown in Figure 2A, in few lymphocytes from A-
T patients the LC3 marker co-localized with lysosome-associated membrane protein 
2 (LAMP2), in contrast to the controls, where no merge signal between LC3 and 
LAMP2 was documented, thus indicating that in the patients, even at basal 
conditions, the autophagy was detectable. A quantitative analysis of LC3 positive 
cells, revealed that in A-T patients the percentage of cells with a puncta pattern was 
much higher than in the controls (82 vs12.25 %) (Figure 2B) and that in A-T patients 
about 4/5 of the total amount of LC3 molecule contained in the cells showed the 
puncta staining pattern (82% puncta vs 18% non-puncta; p = 0.002), thus resulting in 
a LC3 puncta cells/LC3 non-puncta cells ratio much higher in the patients than in the 
controls (6.56 vs 0.37) (Figure 2B). 
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FIGURE 2. Autophagy is active in lymphocytes from A-T patients at basal conditions. A, 
Representative images of freshly isolated lymphocytes from healthy controls and A-T patients 
showing autophagosomes expressing LC3 marker (green punctate dots), lysosomes expressing 
LAMP2 marker (red dots) and autolysosomes (yellow dots). Cells were imaged by fluorescence 
microscopy. B, Percentage of autophagic vesicles positive for LC3 marker and LC3 puncta cells/LC3 
non-puncta cells ratio in freshly isolated lymphocytes from healthy controls and A-T patients. Data 
expressed as mean ± S.E. 
 
Since several genes are activated during autophagy, playing different roles in 
the different steps, we analyzed through quantitative real-time PCR the relative 
expression levels of an array of genes differentially involved in the process. 
 In A-T patients at basal conditions, mRNA expression level of UVRAG, 
involved in the biogenesis of APs, was higher than controls (Figure 3A), in keeping 
with the data obtained by TEM. The evaluation of the mRNA expression level of 
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genes involved in the lysosomes biogenesis and function (CSTF, CSTB, CSTD, GBA, 
GUS, CD63, CSTA, CSTE) revealed that, in A-T patients, at basal conditions, the 
expression of 6 out of the 8 genes analyzed was much higher than in the controls 
(Figure 3A), while under starvation conditions the expression was comparable, thus 
suggesting that in A-T, at basal conditions, the activation of the process was 
constitutively high. Taken together the results indicate that in A-T patients, the 
generation of both the APs and the lysosomes is very active.  Moreover, the 
increased expression of 4 out of 5 cathepsins (CSTB, CSTD, CSTA, CSTE) and of the 
GBA hydrolase mRNAs in A-T at basal conditions indicates that lysosomal 
functionality is activated, as well (Figure 3B). 
 Since we observed an inappropriate APs/ALs ratio at the morphological 
studies in A-T, we also evaluated the expression level of Vps11 and Vps18 mRNAs, 
whose products are involved in vesicular trafficking and fusion. As shown in Figure 
3C, at basal conditions, both Vps11 and Vps18 are less expressed in the patients than 
in the controls. The expression level of Vps18 did not increase even after serum 
starvation, as compared to control expression.  
 To allow the encounter between APs and lysosomes, the vesicles have to be 
in the perinuclear zone. Since in the presence of nutrients, the lysosomes are linked 
to the plasmatic membrane through kinesins, we also evaluated the expression level 
of KIF1Bβ, KIF2A, ARL8A, ARL8B and KIF3C. As shown in the Figure 3D, at basal 
conditions, all the kinesins, and in particular the KIF3C molecule, were more 
expressed in A-T patients than in the controls, thus suggesting that the lysosomes are 
located in the peripheral zone of the cell, not favoring the fusion process between the 
vesicles.   
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FIGURE 3. The accumulation of autophagosomes in lymphocytes from A-T patients is associated to 
a reduced expression level of Vps18 mRNA. A-B, Relative mRNA expression level of genes involved 
in the biogenesis of APs (UVRAG) and in the lysosomes biogenesis and function (CSTF, CSTB, 
CSTD, GBA, GUS, CD63, CSTA, CSTE), infreshly isolated lymphocytes from healthy controls and A-
T patients, at basal conditions and after serum starvation for 2h. C-D, Relative mRNA expression 
level of genes involved in vesicular trafficking and fusion (Vps11 and Vps18), at basal conditions and 
after serum starvation for 2h, and in lysosomal positioning in the cell (KIF1Bβ, KIF2A, ARL8A, 
ARL8B and KIF3C) in freshly isolated lymphocytesfrom healthy controls and A-T patients, at basal 
conditions. Data are expressed as mean ± S.E. 
 
mTORC1 is an important sensor in regulating cell proliferation and inhibiting 
autophagy (35). Several pathways regulate its activation, which eventually results in 
the phosphorylation of downstream targets S6K (ribosomal protein 6 kinase), S6 
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(ribosomal protein 6) and 4EBP1 (eukaryotic initiation factor 4E-binding protein), 
involved in protein synthesis and survival. By contrast, ATM inhibits mTORC1. We 
investigated the phosphorylation status of mTOR (Figure 4A) and its downstream 
targets at basal conditions and after treatment with H2O2 at different time points 
(Figure 4B). We found that in A-T lymphoblastoid cell lines, the phosphorylation 
status of mTOR, S6K, S6and 4EBP1 proteins, was increased, in particular after 30’ 
and 60’ of treatment with H2O2, indicating that in A-T patients mTORC1 is active, 
and that autophagy mechanism is inhibited. Collectively, these data suggest that in 
A-T patients there is a lower ATM-mediated inhibition on mTORC1and of its 
downstream molecules, as compared to the control. 
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FIGURE 4. The activation of autophagy in A-T patients is not dependent on mTORC1 activity. 
Lymphoblastoid cells from A-T patients and controls were treated with 0.2 mM of H2O2 for different 
time points. A, Fractioned lysates were loaded for detection of mTOR and p-mTOR. B, Fractioned 
lysates were also loaded for detection of p-S6K, p-S6, p-4EBPI and housekeeping protein. C, p-
mTOR/mTOR ratio in lymphoblastoid cells from A-T patients and controls. 
 
SQSTM1/p62and LC3are the canonical markers to evaluate the autophagic 
process. In particular, SQSTM1/p62 translocates to the autophagosome formation 
site, where it is incorporated and then degraded (36). Its accumulation reveals an 
impaired autophagic flux (28). LC3-IIamount correlates with the number of 
autophagosomes, and is used as indicator of the autophagosome formation (37). 
Bafilomycin A1 (BAFA1), a specific inhibitor of vacuolar-type H
+
 ATPase of the 
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lysosome, increases LC3-II levels, mainly during H2O2 induced stress, indicating that 
a normal flux occurs. We showed that in A-T patients lyphoblastoid cells, at basal 
conditions, SQSTM1 levels are accumulated as compared to controls (Figure 5A). 
Such increase was more evident in the presence of stress induced for 30’ by H2O2 
(Figure 5A). After treating for 1h with bafilomycin, we found that degradation of 
SQSTM1 was inhibited (Figure 5A), as expected. Furthermore, a synergic effect of 
H2O2 and BAFA1 treatment resulted in a remarkable increase of SQSTM1 level 
(Figure 5A). We also provided evidence that, in A-T lymphoblasts at basal 
conditions, Betamethasone pre-treatment is able to promote the degradation of 
SQSTM1, as shown in the Figure 5A. However, BMZ is ineffective in counteracting 
the effect on the molecule of the H2O2 induced stress (Figure 5A). By contrast, BMZ 
is able to counteract the inhibitory effect of the BAFA1 on SQSTM1 level (Fig 5A). 
In the control, BMZ per se promotes the degradation of SQSTM1. As expected, 
bafilomycin increased LC3-IIexpression under the condition of H2O2, induced stress. 
This increase was even more evident after BMZ pre-treatment. In particular, the 
overexpression of LC3-II after BAFA1 treatment, suggests an enhancement of the 
autophagic flux and a Betamethasone positive effect on the modulation of the 
autophagic process.  
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FIGURE 5. Betamethasone pre-treatment promotes autophagy inducing autophagosome formation 
and degradation. A, Lymphoblastoid cells from A-T patients and healthy controls were pre-treated or 
not with Betamethasone (BMZ) (80 nM) for 2h, and H2O2 (0.2 mM) for 0.5h in the presence or 
absence of 100 nM BAFA1 as indicated. Western blotting was performed to analyze the status of 
LC3, SQSTM1 and Tubulin.  
 
In the present study we documented that lymphocytes isolated from A-T 
patients are characterized by an accumulation of APs, associated with a high 
expression of genes involved in the process of biogenesis and function of APs. This 
accumulation is not coupled to a parallel formation of autolysosomes, indicating the 
inappropriateness of the cell clearance apparatus, which ultimately results in the 
morphological appearance at the TEM of cytoplasmic engulfment of waste material.  
Autophagy is a constitutive lysosomal catabolic process during which, 
cytoplasmic components, damaged proteins and entire organelles are degraded and 
recycled to generate building blocks for anabolic processes. The sequestration of 
cytosolic components within the APs is digested within the ALs after the fusion with 
the lysosomes. Autophagy is markedly induced by stress conditions, such as 
starvation, and has two major purposes: to recycle essential macromolecules and 
energy to be reused in conditions of nutritional scarcity or to clear cell from altered 
intracellular components (38). Neurons are post-mitotic cells, which require effective 
protein degradation to prevent accumulation of toxic aggregates. A growing body of 
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evidence now suggests that dysfunction of autophagy causes accumulation of 
abnormal proteins and/or damaged organelles. Such accumulation has been linked to 
synaptic dysfunction, cellular stress and neuronal death. Abnormal autophagy is 
involved in the pathogenesis of both chronic nervous system disorders, such as 
proteinopathies (Alzheimer’s, Parkinson’s, Huntington’s diseases) and acute brain 
injuries (23). Known originally as an adaptive response to nutrient deprivation in 
mitotic cells, autophagy is now recognized as an arbiter of neuronal survival and 
death decision in neurodegenerative diseases (39). 
Autophagy is a dynamic flux including vesicles biogenesis, fusion between 
APs and lysosomes and, eventually, contents degradation, and thus the increased 
number of APs herein observed may be due to an increased biogenesis or to a 
reduced degradation of the vesicles after the fusion with the lysosomes.  
Moreover, it has recently been reported by Park et al. that autophagy is 
upregulated in response to DNA damage and that impaired cell cycle progression 
mediated through the checkpoint kinase 1 (Chk1), that allows DNA repair, affects 
the functionality of autophagy (40).  
 In keeping with the data obtained by TEM, documenting an accumulation of 
APs, we found in A-T lymphocytes, an increased expression of the UVRAG mRNA, 
which is specifically involved in the initial step of formation of APs, thus 
confirming, also at molecular level, that the stage of biogenesis of APs properly 
occurs in A-T patients. Moreover, the evaluation of CD63, which is expressed on 
lysosomal membrane, revealed an increased mRNA expression in A-T lymphocytes, 
indicating a proper lysosomal biogenesis. 
 An accumulation of APs may be due to abnormalities of regulatory molecules 
(41). Among the genes involved in lysosome functionality, cathepsins (CST), 
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lysosomal hydrolases belonging to the cysteine protease family A, B, D and F, and β-
glucosidase and β-glucuronidase, help degrade unwanted intracellular or endocytosed 
proteins (30). In brain neurons of CST D
-/-
 or CST B
-/-
/CST L
-/-
 mice, the lack of 
CST is responsible for the absence of protein degradation, which results in the 
accumulation of vacuolar structures, a feature similar to what observed in A-T 
lymphocytes. Similarly, in macrophages, the absence of CST S promotes an 
accumulation of APs (42), thus indicating a regulatory role for cathepsin family 
molecules. However, in A-T patients, even in unstimulated conditions, the mRNA 
expression levels of these proteases, CSTB, CSTD, GBA, CSTA and CSTE, are 
increased, thus indicating a constitutive hyperactivation of the lysosomal 
functionality. These data argue against the possibility that the accumulation of APs in 
A-T could be related to a reduced hydrolases activity. 
 The positioning of lysosomes plays an important role in that, only the 
lysosomes localized in the perinuclear area of the cell are able to fuse with APs and 
promote the cell clearance (33). The subcellular re-distribution of lysosomes mostly 
relies on their transport along microtubules mediated by the kinesins. The process 
ultimately leads to the formation of ALs where the degradation occurs. In this study, 
we found an overexpression in A-T cells of the kinesins KIF2A and KIF1B-β and the 
monomeric GTPase ARL8B and its close homologue ARL8A. A very impressive 
increase in KIF3C expression was also found. These results further support the 
inappropriateness in the process of lysosomal trafficking, which does not parallel 
APs formation, thus impairing the autophagic flux. By contrast, the A-T lymphocytes 
show a reduced expression of Vps18 and Vps11 mRNAs, whose protein products are 
involved in the vesicular trafficking and fusion between APs and lysosomes (34, 43). 
Both Vps11 and Vps18 are subunits of the Vps-C core complex also composed of 
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Vps16 and Vps33 (44). In eukaryotic organisms, the Vps-C complex acts as tethering 
factor in endosome- and lysosome-related vesicle fusion process. In particular, the 
down-regulation of Vps18, by knocking-down or by using anti-Vps18 antibody, 
blocks AP-lysosome and early endosome fusion, leading to an accumulation of APs 
and late endosomes in yeast (44). Additional data demonstrate that Vps18 plays a 
prominent role in the process (45). However, the immunofluorescence staining 
experiments revealed that, at a certain extent, the fusion process between APs and 
lysosomes in A-T cells did take place. Thus, we would argue that the reduced 
expression of Vps11 and Vps18 represents the limiting factor of the process, that does 
not allow an autophagic flux at a proper extent. Overall, the data herein reported 
indicate that the accumulation of APs may be due to the inefficacy of their 
degradation as a consequence of the reduced fusion process among APs and 
lysosomes in the perinuclear zone, determined byan altered regulatory control of the 
process. The increase in kinesins expression may be interpreted as an attempt to 
overcome the inappropriate APs-lysosome fusion process. 
Taken together our data indicate that, in A-T lymphocytes, the fusion step 
between APs and lysosomes represents the limiting factor in the autophagy process. 
We identified the Vps18 protein as a potential checkpoint of the process. 
Besides the nuclear activity of ATM, there is evidence that the molecule is 
also localized in the cytosol, within synaptosomal fractions (46), and, in particular, 
on the peroxisomes (47), where it induces pexophagy in response to ROS (48). It is 
also well documented that ATM, in the cytosol, has a role in the autophagy pathway 
(22). In fact, in the presence of elevated ROS levels, ATM activates the tumor 
suppressor TSC2, through LKB1/AMPK pathway, to inhibit mTORC1 and, in turn, 
induces autophagy (25). In this study, we documented in A-T lymphoblasts, an 
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increase of the phosphorylated S6K, S6and 4EBP1 proteins, which are mTORC1 
substrates, and, in particular, under stress conditions. This is in keeping with the 
inhibitory effect of ATM on mTORC1 signaling. In addition, the increased p-
mTOR/mTOR ratio in A-T patients, under stress conditions, further supports the 
ATM-mediated inhibition of mTORC1. Since in this study we found an 
accumulation of APs, this would imply that autophagy is a complex process and that 
the phase of APs formation is dependent on different regulatory pathways, which are 
not dependent on the cytosolic form of ATM. Whether the dysregulation of the 
process, herein described, directly depends on the absence of ATM mediated control 
of the pathway upstream to mTORC1 or rather to the defect in DNA repair remains 
to be further clarified. 
In our recent studies, we documented transient improvement in A-T patients’ 
neurological performance (5) and a paradoxical increase of proliferative response to 
common mitogens (6), after very low dosage of Betamethasone. Improvement of 
cerebellar symptoms during the steroid treatment was inversely correlated with the 
severity of cerebellar atrophy (7). Several studies have focused on the relationship 
between glucocorticoids and autophagy. It is known that GCs are able to induce 
autophagy in different cell types (49, 50), even though the explanation of the intimate 
molecular mechanism by which these drugs lead to this effect is not fully clear. 
In the attempt to explain the beneficial effect of the steroids in A-T, we 
evaluated the effect of Betamethasone on molecular targets implicated in autophagy. 
We found that Betamethasone pre-treatment promoted the degradation of SQSTM1 
protein, which was accumulated in A-T lymphoblastoid cells. The degradation of this 
protein is generally considered to parallel the progression of autophagy. We also 
found an accumulation of LC3-II protein after BMZ treatment, suggesting an 
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enhancement of the autophagic flux and a Betamethasone-mediated positive effect 
on the process.  
 In conclusion, we provide evidence of the inadequacy of the cell clearance 
apparatus in the cell from A-T patients, characterized by an accumulation of un-
degraded APs. The molecular studies led us to identify in the fusion process between 
APs and lysosomes the limiting step,as checkpoint, in the overall process. The data 
herein reported have been submitted as Brief Report on The Journal of Clinical 
Investigation. 
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CHAPTER II 
Severe Combined Immunodeficiencies 
Severe combined immunodeficiency diseases (SCIDs) represent a 
heterogeneous group of rare genetic syndromes responsible for severe dysfunctions 
of the immune system, which share similar clinical manifestations. SCID is the most 
severe form of inherited primary immunodeficiency (PID) and its prevalence is 
approximately 1:100,000 live births, with a higher prevalence in males (1). SCIDs 
are difficult to recognize clinically because so many different infectious scenarios 
can occur. Without a functional cellular and humoral immune system SCID patients 
are susceptible to recurrent infections such as severe bacterial, viral, or fungal 
infections early in life and often present with interstitial lung disease, chronic 
diarrhea, and failure to thrive. In addition, some patients develop skin rashes, usually 
caused by maternal T cells transplacental engraftment during fetal life or by a wide 
autoreaction due to the activation of autologous T cells against skin components(2, 
3). 
Conventionally, SCIDs have been so far classified, on the basis of the 
involvement of different cell lines in the pathogenesis of the disease and of the 
subsequent different clinical immunological phenotypes related to a specific genetic 
defect. T cell–deficient but normal B cell (T−B+) SCID and bothT cell– and B cell–
deficient (T−B−) SCID, in the presence or absence of NK cells (8) (Table 1).  
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SCID Form 
(Deficiency) 
Phenotype Transmission Gene defect Pathogenetic 
mechanism 
JAK3 
γ-chain 
IL-7Rα 
T
-
B
+
NK
-
 
T
-
B
+
NK
-
 
T
-
B
+
NK
+
 
AR 
AR 
AR 
JAK3 
γ-chain 
IL-7Rα 
Altered 
cytokine 
signaling 
ADA  
PNP  
T
-
B
-
NK
-
 
T
-
B+NK
-
 
AR 
AR 
ADA 
PNP 
Accumulation 
of toxic 
metabolites 
RAG 1, RAG 2 T
-
B
-
NK
+
 AR RAG1/RAG2 Defect in 
V(D)J 
recombination 
ARTEMIS, 
KU70/80 
DNA PK-cs, 
DNAligaseIV 
 
T
-
B
-
NK
+
 
 
AR 
ARTEMIS 
KU70/80 
DNA PK-cs 
LIG4 
Defect in 
V(D)J 
recombination 
and DNA-
DSBs repair 
CERNUNNOS/ 
XLF 
T
low
B
low
NK
+
 AR CERNUNNOS/XLF Defect in 
V(D)J 
recombination 
and DNA-
DSBs repair 
Reticular 
Dysgenesis 
T
-
B
-/+
NK
-
 AR AK 2 Increased 
apoptosis 
ZAP 70 T
-
B
+
NK
+
 AR ZAP70 Impaired TCR 
signaling 
MHC I 
MHC II 
T
+
B
+
NK
+
 
T
low
B
+
NK
+
 
AR TAP1/TAP2,TAPASIN 
HLA-DR, HLA-DP, 
HLA-DQ, HLA-DM, 
HLA-DO 
Defect in 
antigen 
presentation 
CORO 1° T
-
B
-
NK
+
 AR CORO1A Abnormal 
actin 
polymerization 
DOCK 8 T
-
B
+
NK
+
 AR DOCK 8 Defective actin 
polymerization 
Nude/SCID T
-/low
B
+
NK
+
 AR FOXN 1 Defective 
intrathymic 
cross-talk 
     
Table 1. SCID classification 
 
This classification helps in directing molecular studies toward a certain 
genetic alteration, since it  is representative of the stage where the blockage occurs 
during the differentiation process (Figure 6). 
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Figure 6.Genetic defects leading SCIDs (8). 
 
Recently, due to the rapid growth of the knowledge in this field, many novel 
forms of SCIDs have been identified. These forms take into account several unusual 
and complex phenotypic presentations, due to non-hematopoietic alterations, leading 
to a pleiotropic phenotype charachterized by  functional impairment of other organs 
different from immune system (8).  
SCID patients often die during the first two years of life if appropriate 
treatments aimed at the reconstitution of the immune system, are not undertaken. 
Fortunately, the bone marrow transplantation (BMT) HLA-identical donor (RID) is 
the optimal treatment for patients affected with SCIDs (51). Moreover, the 
identification of the molecular causes of these forms of SCID has provided the basis 
for better prenatal and postnatal diagnosis, and opening the possibility to a 
potentially successful gene therapy.  
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2.1 Severe combined immunodeficiency-an update 
Recently, Kwan et al., on the basis of data obtained from 11 U.S. newborn 
screening programsin the general population, reported an incidence of SCID of 1 in 
58,000 live-births, an incidence muchhigher than the previous estimate of one in 
100,000 based on retrospective clinical diagnosis of SCID (52). The conventional 
classification for SCIDs, summarized in Table 1, traditionally considered as 
representative of the stage where the blockage occurs during the differentiation 
process, was, until a few years ago, very useful in directing molecular studies toward 
a certain genetic alteration. However, during the last years many new causative gene 
alterations have been identified with peculiar clinical and immunological 
phenotypes. In a few cases, the genetic alteration allows for a normal T cell 
differentiation program but compromises T cell functionality by affecting the initial 
or final phase of intracellular signaling. These functional T cell disorders are 
characterized by immune dysregulation and cancer predisposition, as well as 
infections. In addition, hypomorphic mutations in some SCIDs genes make possible 
the development of non functional oligoclonal T cells that are responsible for a 
complex of clinical conditions that may include hyperinflammation or autoimmunity. 
Many of the novel forms of SCID also show extra-hematopoietic alterations, leading 
to complex phenotypes characterized by functional impairment of organs different 
from primary lymphoid organs, which can make the diagnostic process very complex 
by standard methods. Taking this into account, the traditional international 
classification of SCIDs based on immunophenotype may no longer be optimal for 
clinical and research purposes (53), diagnostic criteria have to be continuously 
updated to take into account these unusual phenotypic presentations. In his work of 
2014, Shearer emphasizes that currentlythere is no consensus among clinical 
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immunologists on how best to diagnose and treat these rare disorders. It is not 
surprising that an important clinical dilemma concerns the distinction of SCIDs from 
other diseases such as combined immunodeficiencies (CIDs). Recently, it was 
proposed that patients who exhibit an absence or a severe reduction of T cells 
(CD3+<300/μL), absence or severe reduction (<10% of the lower limit) of a 
proliferative response to phytohemagglutinin, or a maternal lymphocyte engraftment 
should be defined as having typical SCID (54). Moreover, the European Society for 
Immunodeficiency suggested as criteria for the diagnosis of CID the presence of one 
of the following parameters: one severe infection, an immunodysregulation disorder, 
cancer, familial CID associated with moderate age-related reduction of CD3+,CD4+, 
CD8+ T cells or of naive T cells. However,a cutoff to distinguish SCID from CID 
has not yet been well defined. Nowadays, hematopoietic stem cell transplantation 
(HSCT) still remains the only possible clinical approach for SCID patients, although, 
for two forms of SCIDs, and, probably in the future for other forms, gene therapy is 
considered for treatment. 
The improvement in next generation sequencing technologies, have provided 
to the clinicians, a powerful tool to identify the genetic alterations responsible for 
PIDs of unknown genetic origin,  even though in most cases the genetic cause still 
remains unknown. 
A report on the biological and clinical features of SCID, paying attention to 
the most recently identified forms andto the unusual or extra-immunological clinical 
features, has been published as Review on New York Academy of Science, for the 
manuscript see below.  
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2.2  Common γ chain over-expression in B-precursor acute lymphoblastic 
leukemia primary cells from pediatric patients: implications in leukemia cell 
cycle progression and survival  
The common γ-chain (γc) is a shared component of receptors for IL-2, IL-4, 
IL-7, IL-9, IL-15 and IL-21. These cytokines play a critical role in development, 
proliferation, survival and differentiation of cell types of both the innate and adaptive 
immune systems (55, 56).  
Alterations of the IL-2RG gene, that encodes for γc, leads to X-linked Severe 
Combined Immunodeficiency (X-SCID), a disorder characterized by the absence of 
T and natural killer cell and a normal number of non- functional B cells (57, 58). 
This disorder is fatal in the first months of life without therapy and for which the 
bone marrow transplantation represents the conventional successful therapy.  
Recently, new therapeutic approaches, such as gene therapy, have been 
considered for the immunological reconstitution. In 2 distinct gene therapy trials for 
X-SCID, immunological reconstitution has been documented in 17 out of 20 patients. 
Unfortunately, 5 of these patients developed leukemia and, only in 2 of them an 
insertional mutagenesis in LMO2 oncogene was documented (59, 60). Moreover, it 
was reported in mice that IL2RG cooperates with LMO2 in inducing hematopoietic 
tumors (61). Of note, no clonal lymphoproliferation has been reported, in patients 
receiving gene therapy for ADA deficiency, despite the observation of a similar 
frequency of integration sites near LMO2 and other proto-oncogenes (62, 63). 
Moreover, overexpression of γc, in X-SCID mice, led to T-cell lymphomas and 
thymic hyperplasia in a third of cases, and no common integration site was found in 
these mice (64). These results suggested that insertional mutagenesis was not the 
only cause of leukemogenesis, raising the possibility that IL-2RG is oncogenic per 
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se. In addition, it is noteworthy, that genes involved in normal cellular processes, 
including signal transduction, cell cycle control, DNA repair, cell growth and 
differentiation, such as growth factors and their receptors, transcriptional regulation, 
senescence and apoptosis, have been implicated in cancer. 
By taking advantage from these evidences, we hypothesize that γc could be 
potentially involved in leukemogenesis. In keeping with this, our previous study we 
documented an over-expression of γc protein in continuous malignant hematopoietic 
cell lines, and a direct correlation between its expression and spontaneous cell 
growth.In addition, an increased expression of all D-type cyclins and a direct 
correlation between the amount of γc and cyclins A2 and B1 expression was noted, 
thus implying a critical regulatory role of γc on cell proliferation of continuous 
malignant hematopoietic cells (65). 
 Of note, it is well known that ILs using γc-receptorsplay a role either in T-cell 
development and function, under physiological circumstances, and in enhancing cell 
growth of T-cell Acute Lymphoblastic Leukemia (T-ALL) cells (66, 67). 
 In order to evaluate whether γc molecule is selectively involved in the 
biology of specific types of leukemia, and not only in T-ALL, in this study we 
analyzed the γc expression profile and γc-signaling in different types of leukemia. 
We evaluated the γc expression in γc primary cells of Chronic Myeloid Leukemia 
(CML), Acute Myeloid Leukemia (AML), B-precursor Acute Lymphoblastic 
Leukemia (B-pre ALL), and T-ALL. We also investigated the potential mechanisms 
by which γc exerts its role in leukemia cell proliferation and survival.  
In particular, we evaluated the expression levels of IL2RG mRNA in cells 
derived from bone marrow aspirates of 39 newly diagnosed patients affected with 
CML, AML, B-preALL and T-ALL, and healthy controls, through Real-Time PCR. 
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We found that IL2Rg mRNA expression was increased in leukemic cells as 
compared to healthy control (mean ± SE =1,74 ± 0,21) (Figure 7). In particular, this 
overexpression was found in lymphoblastic leaukemia cells (mean ± SE =2,62 ± 0,4) 
(Figure 7). 
 
 
Figure 7.  IL2RG mRNA expression was increased in leukemia cells. A-B, Total RNA from leukemic 
cells and controls was extracted and reverse transcribed. The expression levels of IL2GR were 
analyzed by qRT-PCR in leukemia cells (n=39) from AML (n=15), CML (n=10), ALL (n=14) 
patients and controls. IL2GR mRNA amount was mainly increased in ALL cells. The relative gene 
expression is a ratio IL2RG/β-actin fold change.  Each histogram represents the mean + SE. 
 
γc-signaling cytokines play a central role in T-cell development and in the mitogenic 
potential of primary T-ALL cells (66, 67), suggesting the implication of γc-signaling 
in this leukemia subtype. Differently from what expected, we found a higher 
expression of IL2RGmRNA in B-pre ALL (mean + SE = 2.55 + 0.4) (P< 0.05) than 
in T-ALL cells (mean + SE = 1.57 + 0.3) (Figure 8). 
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Figure 8. IL2RG mRNA expression was higher in B-pre ALL than in T-ALL cells. The expression 
levels of IL2RG were analyzed by qRT-PCR in B-pre ALL (n=10) and T-ALL (n=4) cells. The 
relative gene expression is a ratio IL2RG/β-actin fold change.  Each histogram represents the mean + 
SE. 
 
The master regulator proteins of cell cycle progression are the cyclin-cdk complexes, 
an evolutionarily conserved family of proline-dependent serine/threonine kinases 
(68).   
 In ALL abnormal expression and function of cell cycle proteins, in particular 
of D-type cyclins, has already been documented in B-cell malignancies (69). These 
cyclins are under the control of PI3-AKT signaling pathway, which is regulated by 
γc. Thus, we investigated expression pattern of D-type cyclins through qRT-PCR in 
B-pre ALL cells. 
 The results showed that D-type cyclins more were expressed in B-pre ALL 
cells than healthy controls (Figure 9). In particular, all the three cyclins were over-
expressed in the B-pre ALL (D1 cyclin:  mean  + SE = 21.90 + 2.8; D2 cyclin: mean 
+ SE = 5.18 + 0.80; D3 cyclin: mean + SE = 3.22 + 0.61) (P<0.05 for D1 cyclin 
expression vs controls) (Figure 9).   
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Figure 9. D1, D2 and D3 cyclins expression levels were increased in B-pre ALL cells. Analysis of D-
type cyclins expression using qRT-PCR revealed up-regulation of all D-type cyclins. The mRNA 
levels were expressed relative to β-actin expression levels.  Each histogram represents the mean + SE. 
 
A direct correlation between IL2RG and cyclins D2 (R = 0.82) and D3 (R = 0.76) 
expression was found, while no correlation between γc expression and cyclin D1 was 
observed (Figure 10). 
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Figure 10. Positive relationship between IL2RG and cyclins D2 and D3 expression levels. A direct 
positive correlation between IL2RG and cyclins D2 and D3 was found, as demonstrated by Pearson 
correlation coefficient (cyclin D2: R = 0.82; cyclin D3: R = 0.76). No correlation between IL2RG and 
cyclin D1 was found. 
 
Cancer development and progression mainly relies on the ability of tumor 
cells to escape apoptosis more than their normal counterpart (70). BCL-2 family 
members, including BCL-2, BCL-XL, BAX, BAD, are involved in the regulation of 
apoptosis (71), and an abnormal expression or function of these proteins has been 
well documented in human cancer (72). Noteworthy, through the activation of PI3-
K/AKT signaling pathway, γc also regulates genes involved in this biological process 
(73). 
 We evaluated the expression level of the anti-apoptotic BCL-XL by 
quantitative qRT-PCR in order to investigate the mechanisms by which γc promotes 
cell survival in B-pre ALL. We observed that in B-pre ALL cells, BCL-XL mRNA 
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was 57% than controls (mean + SE=0.57+0.12) (Figure 11), thus suggesting the 
presence of alternative mechanisms of the pro-survival effect of γc. 
 Recent evidence suggests that autophagy favors cell survival in the tumor 
microenvironment (74). BCL-2 family proteins are involved in autophagy through 
the inhibition of BECLIN-1, an important mediator of autophagy.  
 Therefore, by quantitative qRT-PCR, we observed that the expression level of 
BECLIN-1 mRNA was increased (mean + SE= 4.73 + 0.71) (P<0.05) in B-pre ALL 
as compared with the controls (Figure 11). 
 
 
Figure 11.  γc promotes leukemia cell survival via autophagy through the up-regulation of BECLIN-1. 
BCL-XL and BECLIN-1 mRNA expression was analyzed through qRT-PCR. BCL-XL mRNA was 
57% of controls. BECLIN-1 expression was greatly increased. The mRNA levels were expressed 
relative to β-actin expression levels. Each histogram represents the mean + SE. 
 
To confirm increased BECLIN-1 expression, we performed western blot 
analysis on total cell lysates obtained from B-pre ALL patients. Our results 
demonstrated that amount of BECLIN-1 is increased in B-pre ALL cells as compared 
with control (Figure 12). 
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Figure 12.Western blot confirmed BECLIN-1 up-regulation in B-pre ALL cells. A,Whole cell 
extracts were prepared from B-pre ALL and control cells. BECLIN-1 expression was determined by 
western blotting. The figure represents two different experiments. B,Densitometric analysis of the 
western blotting was performed by using ImageJ program. All data were normalized to β-actin. 
 
In this study, we documented an up-regulation of IL2RG in several primary 
leukemia cells, and, for the first time, in B-pre ALL cells. This finding is unexpected, 
in that it is well established that the γc-signaling pathway under physiological 
circumstances plays a role in the T-cell development.  
 The regulatory role of a number of cytokines, as interleukins and colony-
stimulating factors, on the survival, growth, differentiation and apoptosis of leukemic 
cells has been extensively documented both in vitro and in vivo (75, 76). ILs using 
γc-receptors,along with the role in T-cell function and development, are enhancers of 
cell growth of T-ALL cells (66, 67). Previous studies, through knock-out strategy or 
neutralization of γc-dependent cytokine receptors, have already shown a potential 
 
 57 
clinical implication of the modulation of γc-dependent signaling pathways in cancer 
treatment (56).  
 As for the molecular mechanisms by which γc promotes cell cycle 
progression in B-pre ALL, we investigated D-type cyclins, which are important 
regulators of the passage through the early G1 and late G1 phase of cell cycle, a 
critical check-point that irreversibly directs the cells to undergo one cell division (68, 
77). 
We found that D-type cyclins mRNA expression is increased, with a 
prominent up-regulation of cyclin D1. The overexpresssion of D-type cyclins has 
been previously reported in B-cell malignancies (69, 78-80). Moreover, alterations of 
cyclins D1, D2 and D3 have also been documented in ALL (81). The prominent 
increase in our study of cyclin D1 mRNA in B-pre ALL is in keeping with what 
previously observed in B-cell neoplasias (69, 82), where it was overexpressed, 
differently from normal lymphoid cells, where this cyclin is absent (82). By contrast, 
cyclins D2 and D3 play a role in hematopoiesis also under physiological conditions. 
The cyclin D2-/- murine model exhibits an impairment of B-lymphocyte proliferation 
(83, 84). Cyclin D3
-/-
mice are affected with severe defects in B- and T-lymphocyte 
development and neutrophil maturation (81). 
 In our study, a positive correlation between the amount of γc and the 
expression of cyclins D2 and D3 has also been found.  This would indicate that the 
activation of these cyclins and γc is under an unique regulatory control in B-pre ALL, 
thus being implicated in the pathogenesis of the lymphoproliferation. 
 Due to the role of apoptosis in cancer development (70), we evaluated in B-
pre ALL cells the expression levels of the anti-apoptotic BCL-XL molecule, a 
member of the BCL-2 family proteins. This molecule plays a pivotal role in 
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promoting tumor cell survival (70, 85). In addition, a deregulation of Bcl-2 proteins 
expression has been documented in several types of human cancer (72, 86). We 
found a down-regulation of BCL-XL expression, thus implying the presence of 
alternative, or additional, mechanisms capable to escape cell death through the over-
expression of γc in B-pre ALL cells.   
 The high proliferation rate of cancer cells requires continuous source of 
energy and nutrients, but the tumor microenvironment is not able to supply these 
essential needs for cancer cell survival (87). Several studies highlighted the critical 
role of autophagy in protecting cells against a shortage of nutrients, through removal 
and recycling of damaged molecules and organelles, even though the exact molecular 
and biochemical mechanism by which cancer cells obtain energy sources under these 
limiting conditions, remains to be elucidated (88, 89). In our study, we found in B-
pre ALL cells increased BECLIN-1 mRNA levels and protein amount, as compared 
with controls. Beclin-1 is a component of the class III phosphatidylinositol-3-kinase 
(PI(3)K) complex, that participates in autophagosome nucleation (90). The molecule 
is activated by a number of proteins, including AMBRA1, UVRAG and Bif-1, (91, 
92), and, in turn,promotes the activation of the PI(3)K protein (Vps34) and the 
formation of autophagosomes. Its autophagy-promoting ability is suppressed by the 
antiapoptotic Bcl-2 family members through the direct binding of BH3-domain-only 
(90). 
Evidence indicates that the predominant role of autophagy in cancer cells is to 
confer stress tolerance, which allows tumor cell survival (93). In keeping with this, 
knockdown of essential autophagy genes in tumor cells re-builds or potentiates the 
activation of cell death (94). By contrast, if microenvironment stress persists, 
excessive autophagy may ultimately lead to autophagic cell death (95). 
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Thus, in our study, the prominent up-regulation of BECLIN-1 expression in 
B-pre ALL cells, contextual with the decreased expression of BCL-XL, is in favor of 
a role of autophagy activation in the pro-survival effect of γc, by promoting 
autophagosome nucleation in the absence of the inhibitory effect exerted by BCL-XL 
on BECLIN-1. 
The data here described document for the first time a prominent up-regulation 
of IL2RG expression in B-pre ALL cells, suggesting a potential selective role of γc in 
this leukemia. Importantly, we described the potential mechanisms by which γc may 
promote proliferation and survival in B-pre ALL cells. We demonstrated a direct 
correlation between mRNA levels of IL2RG and cyclins D2 and D3 in B-pre ALL 
cells, thus implying a role of γc in promoting cell cycle progression by 
transcriptional regulation of these genes. Moreover, we observed BECLIN-1 
increased expression in B-pre ALL cells, suggesting the activation of autophagy, as a 
potential mechanism by which γc promotes cell survival. 
Our data imply a role of γc in the pathophysiology in B-pre ALL and further 
studies in this field will contribute to develop innovative therapeutic strategies in this 
leukemia. 
The identification of critical role of γc in pathophysiology should contribute to 
developmore innovative and effective therapies, aimed to inhibit proliferative and 
pro-survival effects activated by γc -receptors. 
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CHAPTER III 
The role of the epithelial cells in the immune system 
The thymus is the primary lymphoid organ that supports T the development 
of fully mature and self-tolerant T cells (96). This organ is organized in two lobes, 
each one divided in two main regions: a cortical area, a medullary and a transitional 
area, named cortico-medullary junction (CMJ), characterized by abundant blood 
vessels (97). These regions provide appropriate cellular interactions, cytokines and 
chemokines required to induce a full thymocyte development, a process intimately 
linked to the specialized functions of thymic stromal cells (TSCs) and to the thymus 
architecture (98). An important feature of the thymic microenvironment relies on its 
three-dimensional (3D) organization, consisting of an ordered architecture of TSCs, 
which may be epithelial or mesenchymal in origin, through which the developing 
thymocytes migrate and mature. This 3D configuration maximizes the interaction of 
developing thymocytes with the supporting stromal cells, allowing a proper 
intercellular cross-talk, integral to the development of either T cells and TSCs (99). 
The intrathymic T-cell development consists of several processes that require 
the dynamic relocation of developing lymphocytes within multiple compartments of 
the thymus (97). The developmental pathway is divided into three subsequent steps, 
charachterized by the expression of specific immunophenotypic patterns: the 
CD4
−
CD8
−
 double negative (DN) stage, the CD4
+
CD8
+
double positive (DP) stage, 
and the CD4
−
CD8
+
 or CD4
+
CD8
−
 single positive (SP) stage (Figure 13). 
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Figure 13. T-cell development and lympho-stromal crosstalk (97). 
 
From the early T-cell lineage progenitor (ETP) stage to the double-negative 3 
(DN3) stage, the T-cell differentiation is independent from the T cell receptor (TCR), 
but is strictly dependent on the migration through the distinct thymic structures 
(100)] and on the expression levels of specific transcription factors. 
When TCR interacts with low-avidity with the peptide-MHC ligands, DP 
thymocytes receive survival signals. This process, referred to as positive selection, 
allows “productive” T cells to potentially react to foreign antigens, but not to self-
antigens. Within the thymus, DP thymocytes are ready to differentiate into single 
positive (SP) cells, CD4+CD8- or CD4-CD8+, that relocate to medulla. At this site, 
newly generate SP thymocytes are further selected by the medullary stromal cells, 
including autoimmune regulator- (AIRE-) expressing mTECs (101). The cells which 
are reactive to tissue-specific self antigens are deleted, thus avoiding autoimmunity.  
 A remarkable number of similarities are shared between the epithelial and 
stromal cells of the thymus and keratinocytes and fibroblasts of the skin. Both thymic 
and skin epithelial cells selectively express the FOXN1 transcription factor, which 
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plays a critical role in differentiation and survival of these specialized cells (97). 
Hassall corpuscles, a product of medullary thymic epithelial cells, contain keratins 
identical to those in the stratum corneum of the skin. In addition, keratinocytes 
express many keratins expressed in TECs. Moreover, the Notch pathway is shared 
between thymic stroma and skin elements, playing an important role in regulating 
epidermal differentiation, early stage thymocyte maturation and T-cell lineage 
commitment (97). By contrast, a major difference between thymus and skin is the 
architecture of each organ, in that the skin epithelial cells are mostly distributed 
along a basement membrane, differently from epithelial cells of the thymus, which 
are organized in a 3D configuration. 
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3.1 Unraveling the link between ectodermal disorders and primary 
immunodeficiencies 
Primary immunodeficiency disorders (PIDs) represent a heterogeneous group 
of inherited disorders characterized by poor or absent function in one or more 
components of the immune system, that result in chronic, recurrent and life-
threatning infections if not promptly diagnosed and treated (2). 
Recent evidence highlights that the skin participates in a host defenses either 
acting as a primary boundary for germs, as the principal site of environment–host 
interactions, or directly in the developmental process of the immune system. As a 
matter of fact, skin and skin annexa abnormalities, such as skin dryness, brittleness 
of hair, nail abnormalities and abnormal dentition, can be not infrequently associated 
with distinct forms of immunodeficiency and may be a warning sign of 
immunodeficiency, since both epidermal and thymic epithelium have ectodermal 
origin. 
Several forms of PIDs are characterized by developmental abnormalities of 
the skin and immunodeficiency. Elevated IgE levels represent the immunological 
hallmark of hyper-IgE syndrome, characterized by severe eczema and susceptibility 
to infections (102). Ectodermal dysplasia (ED) is a group of rare disorders that affect 
tissues of ectodermal origin. Hypoidrotic ED (HED), the most common form, is 
inherited as autosomal dominant, autosomal recessive or X-linked trait (XLHED). 
HED and XLHED are caused by mutations in NEMO and EDA-1 genes, respectively, 
and show similarities in the cutaneous involvement but differences in the 
susceptibility to infections and immunological phenotype (103, 104).  
Alterations in the transcription factor FOXN1 gene, expressed in the mature 
thymic and skin epithelia, are responsible for human and murine athymia and prevent 
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the development of the T-cell compartment associated to ectodermal abnormalities 
such as alopecia and nail dystrophy (105).  
The association between developmental abnormalities of the skin and 
immunodeficiencies suggest a role of the skin as a primary lymphoid organ. 
Recently, it has been demonstrated that a co-culture of human skin-derived 
keratinocytes and fibroblasts, in the absence of thymic components, can support the 
survival of human haematopoietic stem cells and their differentiation into T-lineage 
committed cells (97).  
In the last decades, the field of PID has been deeply studied, eventually 
leading to an overall better knowledge and nosografic re-classification of the 
different forms so far identified. In particular, several novel forms have been 
described unraveling new clinical and genetic aspects. Nevertheless, it has been 
documented that an inappropriate or late diagnosis of PID by clinicians often occurs, 
thus indicating the strong need of an update on the novel clinical associations of 
different forms and alarm signals.  
An overview on this topic and on the most common immune disorders 
associated with ectodermal alterations have been published as Reviews on 
International Reviews of Immunology,  for the manuscript see below. 
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3.2  Molecular evidence for a thymus-independent partial T cell development 
in a FOXN1-/- athymic human fetus 
The Nude/SCID Syndrome (MIM 601705; Pignata Guarino Syndrome), is 
due to genetic alterations  of the FOXN1 transcription factor, that results, both in 
mice and humans, in congenital athymia and hairlessness. This autosomal recessive 
disorder, leads to a severe T-cell immunodeficiency, congenital alopecia of scalp, 
eyebrows and eyelashes. This phenotype, referred as Nude/SCID, was described for 
the first time in humans in 1996 in two sisters originating from a small community in 
the south Italy (106). This phenotype is widely accepted as the human equivalent of 
the similar murine phenotype, reported for the first time by Flanagan in 1966 (107).  
Evidences suggest a T-cell differentiation at extrathymic sites, as intestine and liver 
and tonsil, where probably T cell populations may arise from preexisting precursor 
cells (108-112). 
Recently, our group demonstrated that gut represents an alternative site of T-
cell ontogeny in a FOXN1-independent and thymus-independent fashion. Taking 
advantage of the opportunity to study tissue samples from an athymic human 
Nude/SCID fetus, we demonstrate that, a few rare T lymphocytes are detectable in 
the cord blood, even though a complete blockage of the CD4+ population occurred 
(113). In the Nude/SCID fetus, most of the rare CD3+ cells were CD4-CD8-. 
Moreover, similarly to a control fetus, a CD3-CD7+CD2+ population was found, 
suggesting that the differentiation of this population is FOXN1-independent. In 
human fetal gut, part of the  CD3-CD7+ population develops into CD3+ T cells 
presumably in a thymus-independent manner (114).  
It is known that T-cell and thymus-independent NK-cell precursors express 
the CD7 molecule in bone marrow and liver from the 5
th
 week of gestation (115), 
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then, CD7+ cells migrate to the thymus to become fully mature T cells (116). In the 
absence of the thymus, it is plausible that this population, which also express CD2 
molecule, could originate from extrathymic sites. CD7+CD2+CD3-lymphocytes  
have already been documented in the epithelium of the small intestine (116). 
However, the expression of CD7 but not of the CD2 marker suggests a T-cell lineage 
commitment. In the Nude/SCID and the control fetuses, a CD3-CD7+CD2- 
population was identified, thus supporting the hypothesis that this precursor 
differentiates toward the T-cell rather than NK-cell lineage.  
There is also evidence indicating that CD3+ mature cell population originates 
from CD3-CD7+ population that express the CD8αα homodimer (114). The 
expression of the CD8αα homodimer has only been documented in mice on 
extrathymic derived intraepithelial lymphocytes (IELs) (117), but it is not clear if this 
population is produced in the intestine or rather they require a functional thymus to 
be generated. In our Nude/SCID fetus we found a negligible number of cells 
expressing the CD8αα homodimer, thus indicating the requirement of an intrathymic 
step of differentiation for these cells. 
In our study, we supported the evidence of the local production of T 
lymphocytes in the intestine in a thymus independent fashion by demonstrating the 
presence of CD3+ and few CD8+ cells in the fetal intestin of the Nude/SCID fetus, 
and of CD3ε transcript, indicating that the process if FOXN1-independent. 
The hallmark of the T-cell ontogeny is the TCR gene rearrangement process 
for V(D)J, characterized by distinctive patterns of gene expression, such as RAG1 
and 2 in lymphocytes of both T- and B-cell lineages, which are responsible for the 
DNA cleavage (118). 
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The T-cell commitment is established by the presence of pTα transcript 
(119)-. This molecule associates with the mature TCR α-chain allowing 
rearrangement of the α-chain gene (120). The expression of pTα and RAG genes is 
upregulated during the DN3 stage of the T-cell development also in IELs RAG1, 
indicating that TCR gene rearrangement occurs locally in the intestine (121). In our 
study we found through Real Time PCR, that the relative expression of RAG1 and 
RAG2 was approximately 50% of the control while pTα expression was  10% of the 
control, demonstrating a thymus-independent T-lymphopoiesis in the intestine of the 
Nude/SCID fetus. Moreover, we previously documented an impairement of the 2 Vβ 
families in the Nude/SCID cord blood. In this study, we found that the spectratype of 
intestinal T cells paralleled the cord blood spectratype in that all the families 
expressed in the Cord Blood Mononuclear Cells (CBMC) were also expressed in the 
intestine. This finding indicates that, in the absence of the thymus, the development 
of intestinal lymphocytes only expressing a limited repertoire occurs. 
The expression of CD103 integrin helps the migration of the previousely 
described lymphocytes into the intestine by interacting with the E-cadherin ligand 
expressed on epithelial cells (122). In this study, we didn’t detect CD103 marker in 
the intestine suggesting that the lymphocytes present in the intestine were not 
elsewhere originated cells migrated into the intestine. 
Collectively, the results of this study represent the first formal demonstration 
that an extrathymic lymphopoiesis in the absence of the thymus and in a FOXN1-
independent manner occurs in humans, but this is not able to provide a productive 
immune response in the peripheral blood. 
These data have been published as Article on PlosOne, for the manuscript see 
below. 
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3.3 APECED: a paradigm of complex interactions between genetic 
background and susceptibility factors 
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Distrophy 
(APECED) is a rare autosomal recessive disease (OMIM 240300) which affects 
many tissues especially endocrine glands (123). APECED is caused by mutations in 
the AutoImmune REgulator gene (AIRE), which maps to 21q22.3 and encodes a 55-
kDa protein that acts as a transcription regulator (123). AIRE is predominantly 
expressed in thymic epithelial cells. It is also expressed in monocyte-derived cells of 
the thymus, and in a subset of cells in lymph nodes, spleen and fetal liver. A great 
contribution to the current knowledge of the pathogenesis and the clinical hallmarks 
of the syndrome came out also from the large number of studies performed in AIRE 
knockout mice. These mice display signs of immunological dysregulation as T-cell 
hyperreactivity, perturbation of  the TCR repertoire (124).   
The diagnosis is primarily based on the presence of two out of the three most 
common clinical features: hypoparathyroidism, Addison’s disease, and chronic 
mucocutaneous candidiasis (123). Further clinical or latent autoimmune endocrine 
signs or diseases may be associated. They include hypergonadotropic hypogonadism, 
Type 1 diabetes mellitus, and autoimmune thyroid disease. Non-endocrine 
autoimmune disorders include vitiligo, alopecia, urticaria-like erythema, chronic 
atrophic gastritis with or without pernicious anemia, celiac disease, malabsorption, 
autoimmune hepatitis, rheumatic diseases. Finally, other clinical features such as 
cholelithiasis, ectodermal dystrophy, acquired asplenia, cancer of the mucosae, 
calcifications of basal ganglia and tympanic membranes may also occur (123). The 
presence of chronic Candida infection suggests a T-cell defect toward intracellular 
pathogens as documented by the defective T cell response in patients with APECED. 
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However, the expression of the clinical phenotype is often partial in infancy. In fact, 
most of the patients with the classic triad of symptoms belong to the second or third 
decade of life. In infancy, chronic candidiasis is generally the presenting sign of the 
syndrome, usually appearing before the age of 5 years. Unfortunately, children 
suffering from isolated candidiasis are not investigated for AIRE mutations. This 
leads to underestimate the prevalence of the syndrome in infancy. It is often followed 
by chronic hypoparathyroidism, before the age of 10 years, and later by adrenal 
insufficiency. Further associated diseases may appear from childhood up until the 
fifth decade of life (125). 
Although APECED is the first well  documented example of autoimmune 
disorders inherited as a monogenic disease, there are several genetic or 
environmental factors which influence the onset of the disease and its clinical 
expression. In fact, APECED patients show a variable range of pathological 
manifestations, with each patient presenting a different constellation of affected 
organs and autoantibodies specicfiities. Furthermore, the severity of each individual 
manifestation may profoundly differ between patients carrying the same mutation.  
 Correlation studies so far failed to reveal a correlation between phenotype 
and genotype and, even among siblings with the same genotype, clinical phenotype 
can reveal wide heterogeneity. These data suggest that factors other than the diversity 
of mutation in the AIRE gene affect the phenotype. Associations to specific HLA 
aplotypes have been found for trait components like alopecia, Addison’s disease and 
type 1 Diabetes in APS 1. The associated haplotypes are the same that associate with 
the common, non-APS-1 related forms of these diseases. Only a weak association 
have been observed between the HLA type and autoantibody specificities  in APS-1 
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patients, suggesting that in APS-1 the HLA alleles do not have a strong influence on 
autoantibody formation (126). 
Along with the central tolerance network, several mechanisms are capable to 
contribute in controlling and regulating in the periphery the immune system. These 
factors are involved in the maintenance of homeostasis of peripheral tolerance of 
residual autoreactive clones which escape negative selection within the thymus and 
play a significant role  to prevent or minimize reactivity to self-antigens. Peripheral 
tolerance is attributable to the induction of functional anergy, deletion by apoptosis 
and the suppressive action of regulatory T lymphocytes (Treg). Anergy is a 
mechanism that results in functional inactivation of self-reactive T cells. Clonal T 
cell anergy can be induced upon engagement of the TCR in the absence of co-
stimulatory signals.  Apoptosis takes place through a series of regulated biochemical 
events that follow Fas/FasL interaction, thus resulting in cell death. Treg cells arise 
during the normal process of maturation within the thymus (127) and preferentially 
express high levels of CD25, the transcription factor forkhead box P3 (FoxP3) and a 
considerable number of additional activation surface markers, as transferrin receptor 
and HLA class II antigens. These cells exhibit a vast spectrum of autoimmunity-
preventive activity. Treg cells are naturally anergic and, upon TCR activation, 
potently suppress the proliferation of CD4+CD25- T cells through an antigen-
nonspecific mechanism (128). Moreover, the intimate molecular mechanism by 
which Treg cells mediate suppression still remains unclear. An additional mechanism 
involved in controlling reactivity to self engages in the periphery Natural Killer cells 
(NK) activity. There is strong evidence that clearly show the association between low 
levels of NK cells and NK-cell activity and the development of autoimmunity, 
attributable to failure in deletion of autoreactive clones by cytolisis.  
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An alteration of the fine tuning of one of these processes leads to 
autoimmunity. 
A focus on thecomplex pathogenesis of APECED and on the potential 
interfering factors involved in the clinical expression of the disease, has been 
published as Review on Frontiers in Immunology, for the manuscript see below. This 
review is part of an Issue we hosted, entitled “Thymic stromal alterations and genetic 
disorders of immune system”, for the Editorial see below. 
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CHAPTER IV  
Targeted next generation sequencing as an approach 
to patients with severe forms of congenital 
immunodeficiencies 
Primary immunodeficiency disorders (PIDs) represent a heterogeneous group 
of inherited disorders characterized by poor or absent function in one or more 
components of the immune system, that result in chronic, recurrent and life-
threatning infections if not promptly diagnosed and treated (2). Traditionally, PIDs 
are classified according to the component of the immune system that is primarily 
disrupted: innate or adaptive immunity, the latter comprising antibody deficiencies 
and combined immunodeficiencies. In the last 20 years, thanks to the progress in 
molecular technologies, a remarkable improvement of the knowledge in the field of 
PIDs, concerning both their pathogenetic mechanisms and clinicalfeatures, has been 
observed. 
Nowadays, about 300 forms of well-characterized PIDs have been identified 
underlying complex phenotypes which encompass a wide spectrum of clinical 
features ranging from recurrent bacterial infections to other unusual 
manifestations,such as autoimmune disorders, cancer susceptibility, allergy and 
autoinflammation. In many cases, children affected with novel forms of PIDs also 
show extrahematopoietic alterations, adding to the complexity of the phenotype 
(129). In the more severe forms, as severe combined immunodeficiencies (SCIDs), 
bacterial, viral, and fungal infections are life-threatening conditions (130). With this 
regard, a timely diagnosis may lead to a prompt and appropriate treatment to 
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reconstitute their immune system. Moreover, the early diagnosis of PID is desirable 
for preventing significant disease-associated morbidity and mortality. 
The overall prevalence of the severe forms of PIDs in the general population 
is approximately 1:10.000 live birth. However, a recent study reported that PIDs are 
underdiagnosed and, therefore, they are presumably more common than previously 
estimated. Thus far, the diagnosis of a specific PID has been based on the 
demonstration of a functional immune defect and on the subsequent identification of 
candidate genes, which are selectively involved in the biochemical pathway 
implicated in that specific functional alteration.  
The Sanger sequencing of candidate genes is a costly and time consuming 
procedure, and, not infrequently, unsuccessful. This approach certainly leads to a 
considerable delay between the onset of symptoms and the time of diagnosis, as 
usually reported. However, it should be emphasized that in most cases, the 
identification of the underlying genetic alteration is not possible. 
Moreover, a prompt and accurate diagnosis of PID with this traditional 
approach may be difficult also because of the variety of clinical/immunological 
symptoms. Clinical heterogeneity as different mutations in the same gene can lead to 
different clinical phenotypes. For example, a specific recombination-activating gene 
1 (RAG1) variant encoding for a protein with partial recombinant activity might 
produce Omenn syndrome, a leaky Severe Combined Immunodeficiency or a 
Common Variable Immunodeficiency phenotype. Genetic heterogeneity implies that 
the selection of candidate genes to screen based on the individual patient’s clinical 
and immunological features may not be easy in the majority of cases, since several 
genes may be implicated in a specific phenotype. In addition, different clinical 
presentations are attributed to a single gene defect, reflecting not only the variety of 
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mutations within each gene but also the interference of modifying genetic factors that 
may influence the phenotype, as observed between individuals with the same 
mutation. Finally, it should be outlined that not all the PIDs causing genes are 
known. 
More recently, advances in next generation DNA sequencing allowed new 
gene identification through whole exome or whole genome sequencing (WES, WGS) 
of several forms of PIDs of unknown causes making the genetic identification of 
immunodeficiency syndromes more efficient (9). Only in the last two years, using 
this technology 34 new gene defects have been identified. Most of these 
immunodeficiencies are rare, even though some of them occur more frequently than 
what previously reported, as documented by several groups (10). Based on the 
principle of massively parallel sequencing, NGS technology provides an advanced 
tool to dramatically increase the speed at which DNA can be sequenced at a lower 
cost as compared to the traditional Sanger sequencing approach. 
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4.1 Targeted next generation sequencing revealed MYD88 deficiency in a 
child with chronic Yersiniosis and granulomatous lymphadenitis 
Myeloid differentiation factor (MyD)88 is a key downstream adapter for most 
Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) (131). Its pathway 
regulates the synthesis of several inflammatory cytokines such as IL-1β, IL-6, IL-8, 
interferon (IFN)-α/β, IFN-γ and tumor necrosis factor (TNF)-α (132). MYD88 
deficiency is a very rare, autosomal recessive primary immunodeficiency, associated 
with life-threatening and recurrent pyogenic bacterial infections, including invasive 
pneumococcal disease (133). In MYD88-deficient patients, impaired 
polymorphonuclear neutrophil mobilization and/or frank neutropenia may occur 
from the onset of infection, presumably related to the lack of IL-8 production. 
Gastrointestinal infections are rare (134). Moreover, TLRs play a key role in the 
immunological response to flagellated Gram-negative bacterium (135). Of note, 
Yersinia enterocolitica is able todeactivate TLR-induced signaling pathways, by 
cleaving Myd88, triggering to apoptosis in macrophages (136). This mechanism may 
increase Yersinia virulence also inimmunocompetent hosts. In a recent paper by von 
Bernuth et al, MyD88-deficient mice resulted susceptible to almost nearly all the 
microbes tested, including bacteria, viruses, protozoa and fungi, highlighting the 
importance of TLR in the immuneresponse to different pathogens. By contrast, 
patients with MyD88- or IRAK-4-deficiencies have been shown to be susceptible to 
invasive and non-invasive infections with only a few Gram-positive and Gram-
negative bacteria, maybe as a consequence of the redundancy of the immune system 
(137). However, the predominance of Gram-positive bacteria in patients with 
MyD88 and IRAK-4 deficiencies may result, at least in part, from a limited 
exposition to the different antigens in certain geographic areas. The evidence of 
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chronic Yersiniosis in this patients, expand the variety of organisms, which can lead 
to infections in subject affected with this syndrome. 
 We recently reported the case of a 2-year-old female born to consanguineous 
parents of Rom ethnia, affected with chronic Yersiniosis, recurrent granulomatous 
lymphadenitis, and episodicneutropenia in the absence of recurrent invasive 
pneumococcal disease. Through a targeted next generation sequencing panel, 
including genes responsible for immunodeficiency, we found a homozygous in-
frame deletion (p.Glu66del) in the Myd88 gene, that allowed us to perform a 
diagnosis in this patient.  
These data have been published as Letter to the Editor on Journal of Allergy 
and Clinical Immunology, for the manuscript see below. 
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4.2 Diagnostics of Primary Immunodeficiencies through targeted Next 
Generation Sequencing 
Next Generation Sequencing (NGS) technology represent a powerful, cost-
effective, first-line diagnostic tool for a rapid detection of a genetic alteration, 
particularly in complex cases and represent a valuable and rapid alternative to the 
whole genome sequencing (138). 
In this study we used NGS sequencing panel, including 571 targeted genes 
and WES to study a cohort of 45 patients affected with complex clinical phenotypes, 
highly suggestive for primary immunological defect, in which a diagnosis was not 
obtained through current diagnostic procedures. We enrolled patients who presented 
one or more clinical criteria (such as opportunistic infections, granuloma, chronic 
mucocutaneous candidiasis, intractable diarrhea, bronchiectasis, severe 
autoimmunity, variably associated to syndromic features and/or familiarity for 
similar phenotype) associated to one or more immunological alteration (such as 
abnormal lymphocyte subsets (absolute count < 2 SD of normal values according to 
ESID criteria), proliferative response to mitogens <10% of the CTR, absent/poor 
specific antibody response, hypogammaglobulinemia, high IgE levels (>2000 KU/l), 
absent cytolytic activity, alteration of class switch recombination (CSR) with or 
without hyper-IgM. 
In four patients we found alterations of genes responsible for already 
genetically defined PIDs associated with unusual clinical phenotypes, confirmed at 
functional and molecular level (Table 2). In 8 patients we identified a total 22 gene 
variants in genes implicated in the immune response but not previously associated to 
any known PID that will be further investigated to find a correlation with the 
immunological and clinical features (Table 3). In 1 patient, NGS revealed multiple 
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genetic variants, that were consistent only with some features of the clinical 
phenotype (Table 4). In 10 patients, with a complex disorder not classified in any 
known syndrome, we found a number of genetic variants not proved as relevant for 
the pathogenesis. Eventually, in the remaining 23 patient NGS, including 9 T-NGS 
and 14 WES, did not reveal any variant at all (Table 5). 
The genetic alterations previously mentioned have been divided into 4 
categories: I) genetic alterations associated to a canonical PID phenotype; II) novel 
or already described alterations of genes causing previously defined PIDs associated 
with novel clinical features; III) functionally relevant genetic alterations partially 
consistent with novel clinical phenotypes; IV) multiple genetic variants not 
consistent with functional alterations individually, in whom the link between the 
genotype and that new phenotype is still missing. Thanks to this novel diagnostic 
approach, a defined diagnosis of PID was achieved in a timely manner, in 8 out of 45 
subjects.  
NGS technology represents a cost-effective and rapid first-line genetic 
approach for the evaluation of complex cases of PIDs. The advantage of this 
technique is the simultaneous sequencing of a panel of genes, which might allow 
clinicians to rapidly identify an affected gene, that, probably, would be never sought 
using the traditional approach based on a functional driven hypothesis. Prompt 
diagnosis may allow physicians to get started with the more appropriate treatment, 
which may often be life-saving. 
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Gene Mutation Zigosity Inheritance Clinical and immunological 
phenotype 
CD40L c.373C>T  Hom XL Severe 
hypogammaglobulinemia with 
hyper IgM, neutropenia, P. 
carinii pneumonia, CMV 
infection, intractable diarrhea 
STAT1 c.847T>A  Het AD Chronic mucocutaneous 
candidiasis, recurrent 
pneumonia, hypothyroidism, 
lymphopenia, poor vaccine 
response 
BTK c.1105C>T  Hom XL Agammaglobulinemia 
JAK3 c.856C>T 
 
Hom AR T-B+NK- SCID, chronic 
diarrhea, pathological 
proliferative response to 
mytogens , IgA deficiency 
 
Table 2. Genetic variants associated to typical PID 
 
Gene Mutation Zigosity Inheritanc
e 
Clinical phenotype 
MYD88 c.192_194del Hom AR Chronic yersiniosis and 
terminal ileitis, recurrent severe 
cutaneous granulomatous 
abscesses, hyper IgE, 
hypereosinophilia, neutropenia 
PLDN c.232C>T Hom AR Partial oculocutaneus albinism, 
nystagmus,  recurrent cutaneous 
infections, thrombocytopenia, 
leucopenia, NK deficiency  
DOCK8
/CLEC7
A 
c.3193delA Hom/Hom AR Intractable diarrhea, eczema, 
malignancies (?), food allergies, 
hyper IgE, lymphopenia 
CASP10 c.683C>T 
 
Het AD Acute lymphoblastic leukemia 
treated with allogenic HSCT, 
ethmoiditis, recurrent 
lymphoadenopathy, 
autoimmune cytopenia, 
arthritis, 
hypogammaglobulinemia, 
hyperIgM, IgA deficiency 
Table 3. Genetic variants associated to novel presentation of PID 
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Table 4.  Genetic variants that are not causative of PID, with possible impact on the disease 
 
 
Gene Mutation Zigosity Major clinical features 
CASP10 c.1202_1208del Het Alopecia universalis, 
hyperthyrotropinemia,  type I 
diabetes mellitus, dental enamel 
hypoplasia, developmental 
delay, short stature, candidiasis, 
hepatomegaly, multiple skeletal 
abnormalities, myopia, 
dysmorphic features, 
microcephaly 
DOCK8 
TRL3 
c.1907A>G  
c.2672A>G  
Het Inflammatory bowel disease, 
short stature, aspergillosis, EBV 
infection, low CD4+ 
lymphocyte subset , increased  
CD4 CD8 double negative  T 
cells ,       normal antibody 
response                 
ADA 
 
 
ERCC6 
c.377C>A 
c.1047A>G  
 
c.3262A>G 
c.2697G>A  
Het T-B+NK+ SCID treated with 
bone marrow transplantation, 
Pneumocystis carinii 
pneumonia, recurrent otitis, 
absent ossicular bone  with 
hypoacusis of the right ear, mild 
brain and cerebellar atrophy, 
speech delay, idiopathic 
scoliosis 
 
AP3B1  
PRF 
 
ADAMTS13 
c.787G>T 
c.695G>A 
c.272C>T 
c.2701G>T 
 
 
 
Het Interstitial lung disease                           
CMV infection,esophageal 
candidiasis, strabismus,  
abnormal expression of perforin 
in NK cells, reduction of CD4+ 
lymphocyte subset with increase 
of CD19+ and HLA-DR, 
normal proliferative response to 
mytogens, normal antibody 
response 
CFTR c.2991G>C  Het Hypogammaglobulinemia late 
onset, recurrent pneumonia, 
bronchiectasis, chronic sinusitis, 
cervical and mediastinum 
lymphoadenopathy, recurrent 
abdominal pain, hepatomegaly 
with low grade steatosis, 
splenomegaly 
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Table 5. Genetic variants that are not causative of PID with undetermined  impact on the disease  
Gene Mutation Zigosity Major clinical features 
SYCE2 
LYST 
c.577G>A  
c.10235G>A 
 
 
Het t(11;18)MLT1-AP12 gastric maltoma HP 
+, persistent oral candidiasis, sinusitis; 
lung cystis, chronic cough, recurrent 
fever, hypereosinophilia, reccurent itch, 
reccurent myofasciitis, hyper IgM, altered 
somatic hypermutation, absent CD19+ 
CD20- IgG+ (mature), low CD19+ 
CD27+ IgM+ (memory),  absent CD19+ 
CD27+ IgM-(switched memory) 
ATR 
ARSA 
CASP10 
IKBIKG 
MEFV 
SP110 
UNC13D 
c.5257A>G 
c.869G>A 
c.683C>T 
c.1165C>T 
c.460T>C 
c.1114C>T 
c.335G>C 
Het 
Het 
Het 
Het 
Het 
Het 
Het 
 
Severe aplastic anemia, hepatomegaly, 
Legionella p. and Aspergillus recurrent 
pneumonia, metacarpal deforming 
alterations with bone demineralization, 
abnormal lymphocyte proliferation, 
dilated cardiomyopathy, early retinophaty 
ATRX 
 
MYD88 
DOCK8 
c.2247_2249del 
c.2133_2135del 
c.10_28del 
c.2920C>A 
c.3016C>A 
c.3220C>A 
Het 
Hom 
Het 
Het 
Het 
Het 
Autoimmune adrenal insufficiency, 
autoimmune thyroiditis, 
lymphadenopathy, autoimmune 
thrombocytopenia and neutropenia 
TYK2 c.3488A>G  Het Hypogammaglobulinemia,  familial IgA 
deficiency, hyper IgE, multiple  
bronchiectasis, candidiasis 
TLR3 c.634-10C>A Het Familial IgA deficiency, multiple 
bronchiectasis, recurrent respiratory 
infections, low  IgM levels  
CASP10 
 
ERCC5 
GJC2 
c.1094A>C Het 
 
Het 
Het 
Mild hypogammaglobulinemia, 
undetectable CD16+ lymphocyte levels, 
pervasive developmental disorder 
CD3-
ZETA 
OCRL 
c.301C>T  Het Hypogammaglobulinemia, recurrent 
pneumonia, previous alopecia, behavioral 
disorders, oropharyngeal candidiasis 
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TECHNOLOGIES 
Cells and cell cultures  
Peripheral Blood Mononuclear Cells (PBMCs) were obtained from patients and 
healthy donors by Ficoll-Hypaque (Biochrom, Berlin, Germany) density gradient 
centrifugation. Lymphoblastoid B-cell lines (BCLs) were generated by EBV 
immortalization of patients and healthy donors PBMCs using standard procedures, 
and were grown in RPMI-1640 (Lonza, Verviers, Belgium) supplemented with 10% 
fetal bovine serum (FBS; Gibco, Carlsbad, California), 2 mmol L-glutamine (Gibco, 
Carlsbad, California), 50 g/ml, gentamycine (Gibco, Carlsbad, California), 10% 
Penicillin-Streptomycin (Lonza, Verviers, Belgium), and cultured at 37°C, 5% CO2. 
Serum starvation was induced incubating the cells in medium supplemented with 2 
mmol/L L-glutammine, without FBS, for 2h.  
Cord blood (CB) from the FOXN1
-
/
-
 fetus was obtained by cordocentesis at 16 weeks 
of gestation. Age-matched CB cells from the CEINGE bank of Naples were used as 
control. Fetus parents provided written informed consent.  
Leukemia cells were obtained from the bone marrow of newly diagnosed patients, 
with high leukemia involvement (85-100%), affected by Chronic Myeloid Leukemia 
(CML), Acute Myeloid Leukemia (AML), B-precursor Acute Lymphoblastic 
Leukemia (B-pre ALL) and T-ALL, by using Ficoll-Hypaque (Biochrom) density 
gradient centrifugation. Normal bone marrow cells were obtained from healthy 
donors and used as control cells, through the same procedure. 
For the cytokine mRNA production, PBMC were cultured in RPMI 1640 
supplemented with 1% FBS, for 24 h without stimulation, and then stimulated with 
LPS 1ng/ml, IL-1β 10 ng/ml, TNFα 20 ng/ml or poly(I:C) (TLR3 ligand) 25 μg/ml. 
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For the complementation of patients' fibroblasts with plasmids carrying wild-type 
MYD88,fibroblasts were incubated with a mixture containing Lipofectamine 2000 
reagent (Invitrogen#52887) and plasmids, as previously reported.2 This complex was 
then removed and fibroblastswere incubated for 18 h in DMEM supplemented with 
10% FBS before stimulation. Cytokine Mrnaproduction was assessed in fibroblasts 
cultured in DMEM supplemented with 10% FBS, incubatedfor 48 h without 
stimulation, and then with TNF-α, with IL-1β, with poly(I:C) for 6h. 
 
Proliferative assay  
Cell proliferation was analyzed by the thymidine incorporation assay. For the 
evaluation in vitro of proliferative response to mitogens of PMBCs, cells were 
stimulated with phytohaemagglutinin (PHA; 8 μg/ml), concanavalin A (ConA; 8 
μg/ml), pokeweed (PWM, 10 μg/ml) (Difco Laboratories), phorbol-12- myristate-13-
acetate (PMA; 20 ng/ml) ionomycin (0.5 mM) (Sigma Chemical Co) and Interleukin 
7 (IL-7; 20/ng/ml).  
Cells were plated in triplicate at 1x105 viable cells/well in 96-well plates (BD 
Biosciences), in 200 μl of complete medium for 4 days. Cultures were pulsed with 
0.5 μCi 3H-thymidine for 8 hours before harvesting and the incorporated 
radioactivity measured by scintillation counting. Cell viability was determined using 
trypan blue staining.  
 
Western blot and reagents 
Total lysates were obtained from lymphoblastoid B-cell lines generated by EBV 
immortalization of patients and healthy donors PBMCs. The cells were pre-treated or 
not with 80nM of Betamethasone for 2h, 0.2 mM H2O2 for 30 minutes, or 100nM 
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Bafilomicyn A1 (Sigma-Aldrich, St. Louis, MO) for 1h, washed with ice-cold PBS 
(Lonza, Walkersville, MD) and lysed in 100 μl of lysis solution containing 20 mM 
Tris (pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride (PMSF), 1 mM sodium orthovanadatum (Na3VO4), 5 
μg ml leupeptin and 5 μg ml aprotinin on ice for 45 min. Fractioned cell lysates were 
obtained from lymphoblastoid B-cell lines generated by EBV immortalization of 
patients and healthy donors PBMCs. The cells were treated with 0.2 mM H2O2 for 
15, 30 or 60 minutes, washed with ice-cold PBS and resuspended in Buffer A (10 
mM Hepes/KOH pH 7.9, 1.5 mM MgCl2, 10mMKCl, 0.5mM Dithiothreitol (DTT) 
pH 7.9, 0.5 mM PMSF, 0.5mM  Na3VO4, 5 μg/ml leupeptin and 5 μg/ml aprotinin) 
on ice for 10 minutes. Cells were centrifuged to collect the supernatant containing 
the cytosolic fraction. The pellet was resuspended in Buffer C (20 mM Hepes/KOH 
pH 7.9, 25% glycerol, 420mMNaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 
0.5 mM PMSF, 0.5 mM Na3VO4, 5 μg/ml leupeptin and 5 μg/ml aprotinin) on ice 
for 20 minutes. Cells were centrifuged to collect the supernatant containing the 
nuclear fraction. 
The cell lysates were stored at -80°C. Protein concentration was determined 
by Bio-Rad Protein Assay, based on Bradford’s method. Proteins for LC3, SQSTM1, 
p-S6K, p-S6 and p-4EBP1 were separated on 4-12% NovexNuPAGE SDS-PAGE 
gels (Invitrogen, Carlsbad, CA), while proteins for p-mTOR and mTOR were 
separated on 5% SDS-PAGE. Proteins were electrophoretically transferred onto 
nitrocellulose membranes (Sigma-Aldrich, St. Louis, MO). The membranes were 
then washed three times in wash buffer, blocked and incubated with the specific 
primary Abs for LC3 (Biorbyt, Cambridge, UK), SQSTM1 (Fitzgerald Industries 
International, MA, USA), p-S6K (Thr389) (Cell Signaling Technology), p-S6 
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(Ser235/236) (Cell Signaling Technology MA, USA), p-4EBP1 (Thr37/46) (Cell 
Signaling Technology, MA, USA), p-mTOR (Ser2448) (Merk Millipore, Germany), 
m-TOR (Santa Cruz Biotechnology, TX, USA) or Tubulin (Biorbyt, Cambridge, 
UK). Immune complexes were detected using the appropriate anti-rabbit or anti-
mouse peroxidase-linked Abs. ECL reagent (Bio-Rad, Woodinville, WA, USA) was 
used as detection system for visualization. Densitometric analysis was performed 
using ImageJ software.  
 
Transmission electron microscopy 
PBMCs obtained from patients and healthy donors were washed in PBS and 
centrifuged to obtain a visible pellet. Cells were than fixed with a 1% glutaraldehyde 
and 0.2M Hepes. After dehydration, from each sample thin sections were cut with a 
Leica EM UC7 ultramicrotome and further investigated using a FEI Tecnai-12 (FEI, 
Eindhoven, The Netherlands) electron microscope equipped with a Veletta CCD 
camera for digital image acquisition at different magnifications. 
Autophagosomes were identified on the basis of their ultrastuctural 
morphology. These vesicles have a double membrane usually visible as two 
membrane bilayers, which contain cytosol and/or morphologically intact organelles. 
Autolysosomes were identified on the basis of their characteristic single limiting 
membrane, containing unwanted cytoplasmic material and/or organelles at various 
stages of degradation (139). 
 
Fluorescence microscopy 
PBMCs obtained from patients and healthy donors were washed with PBS (Lonza, 
Walkersville, MD) and spotted on sterile coverslips through Shandon CytoSpin III 
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Cytocentrifuge. Each spot was delimited with the DakoPen (Dako, Denmark). Each 
section was blocked with normal goat serum before staining and then treated with 
1:50 of PerCP-labeled CD3 (BD Pharmingen, San Diego, CA) and 1:100 of FITC-
labeled CD45RA Abs (BD Pharmingen, San Diego, CA) or 1:100 LC3 (Biorbyt, 
Cambridge, UK) and 1:100 LAMP (Biorbyt, Cambridge, UK) antibodies.  
Tissue samples were blocked with normal goat serum before staining and then 
treated with 1:50 of PE-labeled CD4 (Beckman Coulter, Brea, CA) and 1:50 FITC-
labeled CD8 (Beckman Coulter, Brea, CA) or 1:50 APC-labeled CD3 (Beckman 
Coulter, Brea, CA) and FITC-labeled CD7 (Beckman Coulter, Brea, CA),  
Appropriate anti-rabbit or anti-mouse peroxidase-linked secondary Abs were used. 
Nuclear counterstain was visualized with DAPI (4',6-diamidino-2-phenylindole, 0.05 
mg/ml, (Vector Laboratories, CA, USA). Images were acquired by a confocal 
microscope (LSM 510, Zeiss, Germany). 
 
Real-time quantitative reverse transcriptase PCR analysis  
Total RNA from patients and controls PBMCs, from normal human skin fibroblasts, 
normal human thymus, CB mononuclear cells (CBMCs) or intestinal frozen tissue 
was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA), and Phase-lock gel 
columns (Eppendorf, Germany) according to the manufacturer’s instructions. RNA 
was reverse transcribed by Transcriptor First Strand Cdna Synthesis Kit (Roche, 
Germany). The Qpcr reactions were performed in duplicate. The amplification of the 
cDNAs was performed using the SYBR Green and analyzed with the Light 
Cycler480 (Roche Applied Systems, Germany). Cycling conditions comprised an 
initial denaturation at 94°C for 5 min, a phase of annealing/extension specific for 
each gene. A dissociation procedure was performed to generate a melting curve for 
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confirmation of amplification specificity. Primers used are listed in Table 6. Results 
are mean + standard error (SE) of 2 repeat experiments and each gene expression 
was normalized to β-actin as housekeeping gene. The relative transcript abundance 
was represented as –DCt = (Ct gene – Ct reference) and the relative changes in gene 
expression was analyzed using the 2
-DDCt
 method (140). 
 
Table 6. Sequences of oligos used in Real-Time qPCR analysis. 
 Primers Sequence (5’-3’) 
GENE  Forward primer Reverse primer 
UVRAG TGACAATTCGTTGCAGGCAGTTA AGGCAACTTGACACCGCATACA 
VPS11 CCACTTTGATGTGGAGACAGC TGTATCGAAGGGCTTCCTGA 
VPS 18 AGCGTCGCTACCTGGAGAG GTACGTTCGGCTGGCTTC 
CSTF ACAGAGGAGGAGTTCCGCACTA GCTTGCTTCATCTTGTTGCCA 
CSTB AGTGGAGAATGGCACACCCTA AAGAAGCCATTGTCACCCCA 
CSTD AACTGCTGGACATCGCTTGCT CATTCTTCACGTAGGTGCTGGA 
CSTA CAGGCTTTGGTCTTCTCTCCA TCACGCATTCCAGGTCTTTG 
CSTE GGACATGATCCAGTTCACCGA GGTTGGCACACTCCACAGCA 
GBA TGGGTACCCGGATGATGTTA AGATGCTGCTGCTCTCAACA 
GUS ATTGGAGGTGCAGCTGACTG TCCTCATGCTTGTTGACACC 
CD63 TCACGTTTGCCATCTTTCTG TCGAAGCAGTGTGGTTGTTT 
KIF1Bβ GACCAAGCTCAGTGGTCTCTAAG CCAGATGACCTGGTCGTATTGTGC 
KIF2A GCCTTTGATGACTCAGCTCC TTCCTGAAAAGTCACCACCC 
ARL8A AGTCCTGGGTAACAAGCGAGAC GCAAGAGATGGAGTAGCAGCAG 
ARL8B CACCTTCGTCAATGTCATCG CCTATGTCCCAGATCTTTATTGTG 
KIF3C GAAGATGCTGGAGGACCTGCGG GTAGGTGCCCCGGAGCTCCATAG 
IL7Rα GGAGCCAATGACTTTGTGGT CTGCAGGAGTGTCAGCTTTG 
IL2RG TGCTAAAACTGCAGAATCTGGT AGCTGGATTCACTCAGGTTTG 
CyclinD1 AGGTCTGCGAGGAACAGAAGTG TGCAGGCGGCTCTTTTTC 
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CyclinD2 CTGTGTGCCACCGACTTTAAGTT GATGGCTGCTCCCACACTTC 
CyclinD3 GCAGCGCCTTTCCCAACT TCAAAAGGAATGCTGGTGTATGTATC 
BCL-XL GTAAACTGGGGTCGCATTGT TGCTGCATTGTTCCCATAGA 
Beclin-1 GGCTGAGAGACTGGATCAGG CTGCGTCTGGGCATAACG 
CD3ε GATGCAGTCGGGCACTCACT TTGGGGGCAAGATGGTAATG 
RAG1 CATCAAGCCAACCTTCGACAT CAGGACCATGGACTGGATATCTC 
RAG2 CCTGAAGCCAGATATGGTC GTGCAATTCACAGCTGGGCT 
pTα CATCCTGGGAGCCTTTGGT CCGGTGTCCCCCTGAGAG 
β-actin GACAGGATGCAGAAGGAGAT TTGCTGATCCACATCTGCTG 
 
 
Flow cytometry analysis  
In flow cytometry of PBMCs, patients and healthy donors cells were exposed to 
directly-conjugated mouse anti-human monoclonal antibodies (mAbs) with CD45-
APC-Cy7 (BD Biosciences), CD3-PeCy5 (BD Biosciences), and CD-127-
AlexaFluor 488 (Biolegend). The cells were incubated with directly-labelled 
antibody clones at 4°C in the dark for 30 min, washed and resuspended in 100 ml 
PBS. The events in the displayed graphs and dot plots were gated by forward and 
side scatter to exclude dead cells. Analytical flow cytometry was performed using a 
BD FACS Canto II flow cytometer (BD Biosciences). Subsequent data processing 
and preparation for presentation was done using BD FACSDiva software.  
In flow cytometry of CBMCs, FITC-, phycoerythrin (PE)-, allophyocyanincyanine 7 
(APC-Cy7)-, peridin chlorophyll protein (PerCP)- or PECy7-coupled Abs were used 
on CB toward CD45 (2D1), CD7 (MT701), CD2 (RPA-2.10), CD3 (UCHT1), CD8a 
(SK-1), CD8b (2ST8.5H7), CD4 (L200), CD62L (SK11), CD45RA (HI100), CD27 
(L128), CD45RO (UCHL-1), CD103 (Ber-ACT8) from BD Pharmingen, San Diego, 
CA or Beckman Coulter, Brea, CA. FACSCanto II flow cytometer and FACSDiva 
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software (BD Bioscience, San Jose, CA) were used. For each sample, negative 
controls were stained with irrelevant Abs conjugated with the same fluorochrome. 
The ‘‘fluorescenceminus-one’’ (FMO) controls have also been used to define 
precisely the cells that have fluorescence above background levels. Briefly, the 
samples have been stained with all of the reagents except one. 
 
DNA extraction  
Total DNA was isolated from peripheral blood lymphocytes with DNA Blood Mini 
Kit_ (Qiagen, Hilden, Germany). Quantity and quality were determined on the Nano-
Drop_ ND-1000 spectrophotometer (ThermoScientific,Waltham, MA, USA). 
 
Targeted Next Generation Sequencing 
Targeted next generation panel, "TaGSCANv.2" (Targeted Gene Sequencing and 
CustomAnalysis) was run, which includes 572 genes. Briefly, samples were prepared 
for sequencing usingTruSight Rapid Capture with TruSight Inherited Disease Oligos 
(Illumina); the MT genome iscovered at 1000x by the addition of MT oligos during 
enrichment (IDT). Samples were sequencedto at least 2.5Gb on an Illumina MiSeq 
with TruSeq v3 reagents, yielding paired 250 nucleotidereads. Alignment, variant 
calling, and analysis were performed as previously described (141). In this case, 
analysis was customized for immunodeficiency, which limited the genes examined to 
55 (Table 7). Variant analysis was confined to coding and splice variants with a 
minor allele frequency (MAF) of 1% or less in the CMH internal database. Sanger 
sequencing was used to verify the finding and confirm carrier status of both parents. 
 
 
 
 134 
Table 7. List of the 55 studied genes in Targeted Next Generation Sequencing 
ADA 
AP3B1 
ATM 
BLM 
BLOC1S6 
BTK 
CD19 
CD247 
CD3D 
CD3E 
CD3G 
CD40LG 
CFP 
DCLRE1C 
DOCK8 
ERCC2 
ERCC3 
FERMT3 
FOXN1 
FOXP3 
G6PC3 
GTF2H5 
ICOS 
IFNGR1 
IFNGR2 
IKBKG 
IL12B 
IL12RB1 
IL1RN 
IL2RG 
JAK3 
LIG4 
LYST 
MPV17 
MYD88 
NHEJ1 
ORAI1 
PRF1 
RAB27A 
RAG1 
RAG2 
RMRP 
SH2D1A 
SLC35C1 
SP110 
STAT1 
STIM1 
STX11 
ADA 
AP3B1 
ATM 
BLM 
BLOC1S6 
BTK 
CD19 
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Statistical analysis  
All statistical analyses were performed using GraphPad Prism 4.00 and MedCalc for 
Windows. All data were expressed as mean ± standard deviation. Values of p≤0.05 
were considered statistically significant. 
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SUMMARY 
 
 
The immune system is a complex integrated network of chemical and cellular 
mediators that developed during evolution to defend the body from any form of 
chemical, traumatic or infective insult to their integrity.  
A proper immune response relies on the innate immunity, that is responsible for a 
first line of defense against aggression and the aspecific recognition of a limited 
repertoire of antigens, and, later, on the adaptative immunity which includes 
chemical and cellular mediators responsible for a more powerful and specific 
defensive response from any form of antigen. Alterations of any part of the immune 
response results in failure of host defense and, in particular, of immunodeficiency, 
autoimmunity and cancer predisposition.  
Primary immunodeficiency disorders (PIDs) are rare inherited disorders 
characterized by poor or absent function in one or more components of the immune 
system, that result in chronic, recurrent and life-threatning infections if not promptly 
diagnosed and treated (2). Traditionally, PIDs are classified according to the 
component of the immune system that is primarily disrupted: innate or adaptive 
immunity. In the last 20 years, thanks to the progress in molecular technologies, a 
remarkable improvement of the knowledge in the field of PIDs, concerning both their 
pathogenetic mechanisms and clinical features, has been observed. Nowadays, about 
300 forms of well-characterized PIDs have been identified underlying complex 
phenotypes which encompass a wide spectrum of clinical features ranging from 
recurrent bacterial infections to other unusual manifestations, such as autoimmune 
disorders, cancer susceptibility, allergy and auto inflammation (8, 142). However, a 
recent study reported that PIDs are underdiagnosed and, therefore, they are 
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presumably more common than previously estimated. Thus far, the diagnosis of a 
specific PID has been based onthe demonstration of a functional immune defect and 
on the subsequent identification of candidate genes, which are selectively involved in 
the biochemical pathway implicated in that specific functional alteration. 
In this thesis, during the three years of my PhD program, I have contributed 
to elucidate “Congenital Immunodeficiencies: novel diagnostic and therapeutic 
approach”, through the clinical, cellular, functional and molecular study of some 
Immunological disorders. In particular, my research work has been focused on the 
study of the potential involvement of autophagy in the pathogenesis of Ataxia 
Telangiectasia, and the potential positive effect of glucocorticoids on the rescue of a 
proper cell clearance process in lymphocytes of the patients affected with this 
disease. 
Moreover, I contributed in the characterization of the potential oncogenic role 
of the common gamma chain (γc) in primary human hematopoietic malignant cell 
lines, by evaluating the molecular mechanisms by which this protein promotes tumor 
growth. 
In addition I contributed to better define the role of the epithelial cells in the 
immune system and of thymic stromal alterations responsible for immunological 
disorders. Eventually I participated to two studies focused on the application of Next 
Generation Sequencing technique for the diagnosis of immunodeficiencies.  
Overall, the results obtained during my PhD course could be useful both in 
the clinical practice and in the basic research of immunological diseases. 
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APPLICATIONS TO GRANT PROPOSALS 
 
1. Futuro in Ricerca-Call for MIUR Application 2013  with a project entitled: 
“Characterization of the potential oncogenic role of γc by exploring its 
modulatory activity on genes related to growth signaling, cell cycle control and 
survival, and through its post-transcriptional miRNAs-mediated regulation”.  
2. Sparks Project grant application for A-T 2013 with a project entitled: 
“Evaluation of the cytoplasmic role of ATM kinase in the autophagy-lysosomal 
pathway and its pathogenic implication in Ataxia-Telangiectasia: potential 
modulatory effect of Betamethasone”. 
3. Telethon Grant Proposals-Call for Applications 2014  with a project entitled: 
“Evaluation of the cytoplasmic role of ATM kinase in the autophagy-lysosomal 
pathway and its pathogenic implication in Ataxia-Telangiectasia: potential 
modulatory effect of Betamethasone”. 
4. Telethon Grant Proposals-Call for Applications 2015 with a project entitled: 
“Evaluation of the cytoplasmic role of ATM kinase in the autophagy-lysosomal 
pathway and its role in the pathogenesis of Ataxia Telangiectasia: potential 
modulatory effect of Betamethasone or other FDA approved drugs evaluated 
through High Content Screening”. 
5. PRIN - Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale - 
Call for MIUR Application 2015, with a project entitled: “Targeted next 
generation sequencing as an approach to patients with severe forms of 
congenital immunodeficiencies”. 
6. Jeffrey Modell Foundation – Grant for Immunodeficiency Disorders on 
Trialect, with a project entitled: “In vitro development of medullary thymic 
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epithelial cells (mTECs) obtained by the Reprogramming technology, to 
support HSC differentiation into fully mature single positive T cells on a 3D 
thymic organoid”. 
7. Action for A-T - Call for Ataxia Telangiectasia research applications with a 
project entitled: “Evaluation of the link between autophagy and Ataxia-
Telagiectasia and of potential modulatory effect of Betamethasone or other 
FDA approved drugs evaluated through High Throughput Screening”. 
 
 
 
 
 
 
  
 
 143 
SCIENTIFIC PRODUCTION 
 
LIST OF PUBLICATIONS: 
1. De Martino L., Capalbo D., Improda N., D' Elia F., Di Mase R., D’Assante R., 
D' Acunzo I., Pignata C., Salerno M. APECED: A paradigm of complex 
interactions between genetic background and susceptibility factors. Front 
Immunol. 4:331, 2013.  
2. Fusco A., Panico L., Gorrese M., Bianchino G., Barone M.V., Grieco V., 
Vitiello L., D’Assante R., Romano R., Palamaro L., Scalia G., Del Vecchio L., 
Pignata C.  Molecular evidence for a thymus-independent partial T cell 
development in a FOXN1-/- athymic human fetus. PLoS One 8(12):e81786, 
2013.  
3. Pignata C., D’Assante R., Sousa AE. Thymic stromal alterations and genetic 
disorders of immune system. Front Immunol. 6:81, 2015.  
4. D’Assante R., Fusco A., Palamaro L., Giardino G., Gallo V., Cirillo E., Pignata 
C. Unraveling the link between ectodermal disorders and primary 
immunodeficiencies. Int Rev Immunol. [Epub ahead of print], 2015.  
5. Cirillo E., Giardino G., Gallo V., D'Assante R., Grasso F., Romano R., Di Lillo 
C., Galasso G., Pignata C. Severe combined immunodeficiency-an update. Ann 
N Y Acad Sci. 1356(1):90-106, 2015.  
6. Giardino G., Gallo V., Somma D., Farrow E.G., Thiffault I., D’Assante R., 
Donofrio V., Paciolla M., Ursini M.V., Leonardi A., Saunders C.J., Pignata C. 
Targeted next generation sequencing revealed MYD88 deficiency in a child with 
chronic Yersiniosis and granulomatous lymphadenitis. J Allergy Clin Immunol. 
IN PRESS, 2015. 
 
 144 
MEETING ABSTRACTS AND COMMUNICATIONS: 
 
1. Cirillo E., Gallo V., Giardino G., Galasso G., Romano R., D'Assante R., 
Genesio R., Baldini A., Nitsch L., Pignata C. DiGeorge-like syndrome in a child 
with a 3p12.3 deletion involving miRNA-4273 born to a diabetic mother. XVI 
meeting of the European Society for Immunodeficiencies, Prague 29 October-1 
November 2014. (Poster) 
2. Giardino G., Cirillo E., Gallo V., D'Assante R., Paciolla M., Ruggiero G., 
Ursini M.V., Carsetti R., Puel A., Pignata C. Chronic mucocutaneous 
candidiasis, recurrent herpetic infections and suppurative eyelid infections in a 
patient carrying a novel gain-of-function mutation in the STAT1 DNA-binding 
domain. XVI meeting of the European Society for Immunodeficiencies, Prague 
29 October-1 November 2014. (Poster) 
3. Gallo V., Cirillo E., Giardino G., D'Assante R., Spennato P., Cinalli G., Pignata 
C. Intrathecal amphotericin B therapy in a patient with X-linked chronic 
granulomatous disease and refractory cerebral invasive aspergillosis. XVI 
meeting of the European Society for Immunodeficiencies, Prague 29 October-1 
November 2014. (Poster) 
4. Romano R., D'Assante R., Bianchino G., Grieco V., Parasole R., Poggi V., 
Palamaro L., Fusco A., Scotto Di Marco G., Pignata C. Gamma chain is 
prominently overexpressed in B-pre acute lymphoblastic leukemia cells. XVI 
meeting of the European Society for Immunodeficiencies, Prague 29 October-1 
November 2014. (Poster) 
5. Fusco A., Polishchuk E., D'Assante R., Palamaro L., Ballabio A., Pignata C. 
Aberrant autophagic vesicles in the lymphocytes from patients affected with 
 
 145 
Ataxia-Telangiectasia. XVI meeting of the European Society for 
Immunodeficiencies, Prague 29 October -1 November 2014. (Poster)  
6. D’Assante R., Fusco A., Polishchuk E., Palamaro L., Ballabio A., Pignata C.. 
Accumulation of autophagic vesicles in lymphocytes from patients affected with  
A-T. Ataxia Telangiectasia Clinical Research Conference 2014, Nijmegen, the 
Netherlands, 13-15 November 2014. (Oral presentation)  
7. Fusco A., D’Assante R., Scalia G., Palamaro L., Del Vecchio L, Pignata C. The 
low proliferation rate of lymphocytes from A-T patients directly correlates to the 
reduced surface expression of IL7Rα trafficked through autophagic vescicles. 
Ataxia Telangiectasia Clinical Research Conference 2014, Nijmegen, the 
Netherlands, 13-15 November 2014. (Poster) 
 
  
 
 146 
REFERENCES 
 
1. Fischer A, Le Deist F, Hacein-Bey-Abina S, Andrè-Schmutz I, Basile Gde S, 
de Villartay JP, et al. Severe combined immunodeficiency. A model disease for 
molecular immunology and therapy. Immunol Rev. 2005;203:98-109. 
2. Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, 
et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 
2009;124:1161-78. 
3. Palmer K, Green TD, Roberts JL, Sajaroff E, Cooney M, Parrott R, et al. 
Unusual clinical and immunologic manifestations of transplacentally acquired 
maternal T cells in severe combined immunodeficiency. J Allergy Clin Immunol. 
2007;120:423-8. 
4. Zannolli R, Sabrina B, Betti G, Salvucci S, Plebani A, Soresina A, et al. A 
randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia 
telangiectasia. Mov Disord. 2012;27:1312-6. 
5. Broccoletti T, Del Giudice E, Amorosi S, Russo I, Di Bonito M, Imperati A, 
et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia 
patients. Eur J Neurol. 2008;15:223-8. 
6. Broccoletti T, Del Giudice E, Cirillo E, Vigliano I, Giardino G, Ginocchio 
VM, et al. Efficacy of Very-low-dose betamethasone on neurological symptoms in 
ataxia-telangiectasia. Eur J Neurol. 2011;18:564-70. 
7. Russo I, Cosentino C, Del Giudice E, Broccoletti T, Amorosi S, Cirillo E, et 
al. In ataxia-teleangiectasia betamethasone response is inversely correlated to 
cerebellar atrophy and directly to antioxidative capacity. Eur J  Neurol. 2009;16:755-
9. 
 
 147 
8. Aloj G, Giardino G, Valentino L, Maio F, Gallo V, Esposito T, et al. Severe 
combined immunodeficiences: new and old scenarios. Int Rev Immunol. 2012;31:43-
65. 
9. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines 
for genetic studies in single patients: lessons from primary immunodeficiencies. J 
Exp Med. 2014;211(11):2137-49. 
10. Conley ME, Casanova JL. Discovery of single-gene inborn errors of 
immunity by next generation sequencing. Curr Opin Immunol. 2014;30:17-23. 
11. Rotman G, Shiloh Y. ATM: from gene to function. Hum Mol Genet. 
1998;7:1555-63. 
12. Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic 
strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007;81-82:129-47. 
13. Reina-San-Martin B, Nussenzweig MC, Nussenzweig A, Difilippantonio S. 
Genomic instability, endoreduplication, and diminished Ig class-switch 
recombination in B cells lacking Nbs1. Proc Natal Acad Sci USA. 2005;102:1590-5. 
14. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell 
signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759-69. 
15. Yang DQ, Kastan MB. Participation of ATM in insulin signalling through 
phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000;2:893-8. 
16. Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and 
treatment. Semin Pediatr Neurol. 2003;10:173-82. 
17. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA 
Repair. 2004;3:1187-96. 
 
 148 
18. Dehkordy SF, Aghamohammadi A, Ochs H, Rezaei N. Primary 
Immunodeficiency Diseases Associated with Neurologic Manifestations. J Clin 
Immunol. 2012;32:1-24. 
19. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. 
Survival probability in ataxia telangiectasia. Arch Dis Child. 2006;91:610-1. 
20. Driessen GJ, Ijspeert H, Weemaes CM, Haraldsson A, Trip M, Warris A, et 
al. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed 
B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin 
Immunol. 2013;131:1367-75. 
21. Yang DQ, Halaby MJ, Li Y, Hibma JC, Burn P. Cytoplasmic ATM protein 
kinase: an emerging therapeutic target for diabetes, cancer and neuronal 
degeneration. Drug Discov Today. 2011;16:332-8. 
22. Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL, et al. 
Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated 
suppression of mTORC1. Proc Natl Acad Sci U S A. 2013;110:2950-7. 
23. Xilouri M, Stefanis L. Autophagy in the central nervous system: implications 
for neurodegenerative disorders. CNS Neurol Disord Drug Targets. 2010;9:701-19. 
24. Pallardó FV, Lloret A, Lebel M, d'Ischia M, Cogger VC, Le Couteur DG, et 
al. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: 
Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. 
Biogerontology. 2010;11:401-19. 
25. Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, et al. ATM 
signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc 
Natal Acad Sci USA. 2010;107:4153-8. 
 
 149 
26. Hardie DG. AMPK sensing energy while talking to other signaling pathways. 
Cell Metab. 2014;20:939-52. 
27. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control 
cell growth and survival. Cell. 2003;115:577-90. 
28. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, 
Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring 
autophagy. Autophagy. 2012;8:445-544. 
29. Kim JH, Hong SK, Wu PK, Richards AL, Jackson WT, Park JI. 
Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression 
levels. Exp Cell Res. 2014;327:340-52. 
30. Sardiello M, Palmieri M, Di Ronza A, Medina LD, Valenza M, Gennarino 
VA, et al. A gene network regulating lysosomal biogenesis and function. Science. 
2009;325:473-7. 
31. Settembre C, Ballabio A. TFEB regulates autophagy: an integrated 
coordination of cellular degradation and recycling processes. Autophagy. 
2011;7:1379-81. 
32. Settembre C, Di Malta C, Polito VA, Arencibia MG, Vetrini F, Erdin S, et al. 
TFEB links autophagy to lysosomal biogenesis. Science. 2011;332:1429-33. 
33. Korolchuk VI, Rubinsztein DC. Regulation of autophagy by lysosomal 
positioning. Autophagy. 2011;7:927-8. 
34. Liang C, Lee JS, Inn KS, Gack MU, Li Q, Roberts EA, et al. Beclin1-binding 
UVRAG targets the class C Vps complex to coordinate autophagosome maturation 
and endocytic trafficking. Nat Cell Biol. 2008;10:776-87. 
 
 150 
35. He B, Zhang N, Zhao R. Dexamethasone downregulates SLC7A5 expression 
and promotes cell cycle arrest, autophagy and apoptosis in BeWo cells. J Cell 
Physiol. 2016;231:233-42. 
36. Birgisdottir AB, Lamark T, Johansen T. The LIR motif - crucial for selective 
autophagy. J Cell Sci. 2013;126:3237-47. 
37. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. 
Autophagy. 2007;3:542-5. 
38. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 
2011;147:728-41. 
39. Son JH, Shim JH, Kim KH, Ha JY, Han JY. Neuronal autophagy and 
neurodegenerative diseases. Exp Biol Med. 2012;44:89-98. 
40. Park C, Suh Y, Cuervo AM. Regulated degradation of Chk1 by chaperone-
mediated autophagy in response to DNA damage. Nat Commun. 2015;6:6823. 
41. Repnik U, Stoka V, Turk V, Turk B. Lysosomes and lysosomal cathepsins in 
cell death. Biochim Biophys Acta. 2012;1824:22-33. 
42. Pan L, LI Y, Jia L, Qin Y, Qi G, Cheng J, et al. Cathepsin S deficiency results 
in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-
induced cardiac inflammation. PLoS One. 2012;7:e35315. 
43. Richardson SC, Winistorfer SC, Poupon V, Luzio JP, Piper RC. Mammalian 
late vacuole protein sorting orthologues participate in early endosomal fusion and 
interact with the cytoskeleton. Mol Biol Cell. 2004;15:1197-210. 
44. Nickerson DP, Brett CL, Merz AJ. Vps-C complexes: gatekeepers of 
endolysosomal traffic. Curr Opin Cell Biol. 2009;21:543-51. 
 
 151 
45. Ostrowicz CW, Brocker C, Ahnert F, Nordmann M, Lachmann J, Peplowska 
K, et al. Defined subunit arrangement and rab interactions are required for 
functionality of the HOPS tethering complex. Traffic. 2010;11:1334-46. 
46. Li J, Han YR, Plummer MR, Herrup K. Cytoplasmic ATM in neurons 
modulates synaptic function. Curr Biol. 2009;19:2091-6. 
47. Watters D, Kedar P, Spring K, Bjorkman J, Chen P, Gatei M, et al. 
Localization of a portion of extranuclear ATM to peroxisomes. J Biol Chem. 
1999;274:34277-82. 
48. Zhang J, Tripathi DN, Jing J, Alexander A, Kim J, Powell RT, et al. ATM 
functions at the peroxisome to induce pexophagy in response to ROS. Nat Cell Biol. 
2015;17(10):1259-69. 
49. Zhao Y, Zuo Y, Huo H, Xiao Y, Yang X, Xin D. Dexamethasone reduces 
ATDC5 chondrocyte cell viability by inducing autophagy. Mol Med Rep. 
2014;9:923-7. 
50. Shi J, Wang L, Zhang H, Jie Q, Li X, Shi Q, et al. Glucocorticoids: dose-
related effects on osteoclast formation and function via reactive oxygen species and 
autophagy. Bone. 2015;79:222-32. 
51. Fisher A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, et al. 
European experience of bone-marrow transplantation for severe combined 
immunodeficiency. Lancet. 1990;336:850-4. 
52. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et 
al. Newborn screening for severe combined immunodeficiency in 11 screening 
programs in the United States. JAMA. 2014;312:729–38. 
53. Maggina P, Gennery AR. Classification of primary immunodeficiencies: 
Need for a revised approach? J Allergy Clin Immunol. 2013;131:292-4. 
 
 152 
54. Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et 
al. Recommendation for live viral and bacterial vaccines in immunodeficient patients 
and their close contacts. J Allergy Clin Immunol. 2014;133:961-6. 
55. Vigliano I, Fusco A, Palamaro L, Aloj G, Cirillo E, Salerno MC, et al. g 
Chain transducing element: a shared pathway between endocrine and immune 
system. Cell Immunol. 2011;269:10-5. 
56. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T 
cells by gc family cytokines. Nat Rev Immunol. 2009;9:480-90. 
57. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, et al. 
Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 
receptor. Science. 1993;17:1877-80. 
58. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunl. 
2001;1:200-8. 
59. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et 
al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of 
SCID-X1. J Clin Invest. 2008;118:3132-42. 
60. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, 
Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations 
causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 
2008;118:3143-50. 
61. Davé UP, Akagi K, Tripathi R, Cleveland SM, Thompson MA, Yi M, et al. 
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias 
induced in SCID-X1 patients following retroviral gene therapy. PloS Genet. 
2009;5:e1000491. 
 
 153 
62. Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A, et al. 
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID 
patients treated with stem cell gene therapy. J Clin Invest. 2007;117:2233-40. 
63. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, 
Hu J, et al. Vector integration is nonrandom and clustered and influences the fate of 
lymphopoiesis in SCID-X1 gene therapy. J Clin Invest. 2007;117:2225-32. 
64. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. Gene therapy: 
therapeutic gene causing lymphoma. Nature. 2006;440:1123. 
65. Vigliano I, Palamaro L, Bianchino G, Fusco A, Vitiello L, Grieco V, et al. 
Role of the common g chain in cell cycle progression of human malignant cell lines. 
Int Immunol. 2012;24:159-67. 
66. Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA, Cardoso AA. 
Common g chain-signaling cytokines promote proliferation of T-cell acute 
lymphoblastic leukemia. Haematologica. 2004;89:1459-67. 
67. Ribeiro D, Melao A, Barata JT. IL-7R-mediated signaling in T-cell acute 
lymphoblastic leukemia. Adv Biol Regul. 2013;53:211-22. 
68. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. 
Cell Dev Biol. 1997;13:261-91. 
69. Cao X, L. F, Fang C, Zhu DX, Dong HJ, Wang DM, et al. The expression of 
SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative 
diseases. Med Oncol. 2012;29:1190-6. 
70. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100:57-70. 
71. Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold 
Spring Harb Perspect Biol. 2012;4:a009829. 
 
 154 
72. Scarfò L, Ghia P. Reprogramming cell death: BCL2 family inhibition in 
hematological malignancies. Immunol Lett. 2013;155:36-9. 
73. Walsh ST. Structural insights into the common c-chain family of cytokines 
and receptors from the interleukin-7 pathway. Immunol Rev. 2012;250:303-16. 
74. Roy S, Debnath J. Autophagy and tumorigenesis. Semin Immunopathol. 
2010;32:383-96. 
75. Nakase K, Kita K, Miwa H, Nishii K, Shikami M, Tanaka I, et al. Clinical 
and prognostic significance of cytokine receptor expression in adult acute 
lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor 
prognosis. Leukemia. 2007;21:326-32. 
76. Wu S, Gessner R, von Stockelberg A, Kirchner R, Henze G, Seeger K. 
Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic 
leukemia. Cancer. 2005;103:1054-63. 
77. Ho A, Dowdy SF. Regulation of G(1) cell-cycle progression by oncogenes 
and tumor suppressor genes. Curr Opin Genet Dev. 2002;12:47-52. 
78. Meyerson HJ, MacLennan G, Husel W, Cocco A, Tse W, Lazarus HM, et al. 
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 
identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in 
chronic lymphocytic leukemia. Am J Clin Pathol. 2006;125:241-50. 
79. Sonoki T, Harder L, Horsman DE, Karran L, Taniguchi I, Willis TG, et al. 
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. 
Blood. 2001;98:2837-44. 
80. Casimiro MC, Velasco-Velasquez M, Aguirre-Alvarado C, Pestell RG. 
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past 
and present. Expert Opin Investig Drugs. 2014;23:295-304. 
 
 155 
81. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, et al. 
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer 
Cell. 2003;4:451-61. 
82. Specht K, Kremer M, Müller U, Dirnhofer S, Rosemann M, Höfler H, et al. 
Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time 
reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res. 
2002;8:2902-11. 
83. Solvason N, Wu WW, Parry D, Mahony D, Lam EW, Glassford J, et al. 
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. 
Int Immunol. 2000;12:631-8. 
84. Lam EW, Glassford J, Banerji L, Thomas NS, Sicinski P, Klaus GG. Cyclin 
D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the 
antigen receptor and CD40. J Biol Chem. 2000;275:3479-84. 
85. Johnstone RW. Deamidation of Bcl-X(L): a new twist in a genotoxic murder 
mystery. Mol Cell. 2002;10:695-7. 
86. Dewson G, Kluck RM. Bcl-2 family-regulated apoptosis in health and 
disease. Cell Health and Cytoskeleton. 2010;2:9-22. 
87. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, et al. 
Autophagy is activated in colorectal cancer cells and contributes to the tolerance to 
nutrient deprivation. Cancer Res. 2007;67:9677-84. 
88. Moreau K, Luo S, Rubinsztein DC. Cytoprotective roles for autophagy. Curr 
Opin Cell Biol. 2010;22:206-11. 
89. Jin S, White E. Role of autophagy in cancer: management of metabolic stress. 
Autophagy. 2007;3:28-331. 
 
 156 
90. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates 
autophagy and apoptosis. Cell Death Differ. 2011;18:571-80. 
91. Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, et al. Autophagic and 
tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell 
Biol. 2006;8:688-99. 
92. Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, et al. 
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and 
tumorigenesis. Nat Cell Biol. 2007;9:1142-51. 
93. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. 
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and 
tumorigenesis. Cancer Cell. 2006;10:51-64. 
94. White E, DiPaola RS. The double-edged sword of autophagy modulation in 
cancer. Clin Cancer Res. 2009;15:5308-16. 
95. Xu Y, Xia X, Pan H. Active autophagy in the tumor microenvironment: a 
novel mechanism for cancer metastasis. Oncol Lett. 2013;5:411-6. 
96. Boehm T. Thymus development and function. Curr Opin Immunol. 
2008;20:178-84. 
97. Romano R, Palamaro L, Fusco A, Giardino G, Gallo V, Del Vecchio L, et al. 
FOXN1: A Master Regulator Gene of Thymic Epithelial Development Program. 
Front Immunol. 2013. 
98. Anderson G, Jenkinson WE, Jones T, Parnell SM, Kinsella FAM, Withe AJ, 
et al. Establishment and functioning of intrathymic microenvironments. 
Immunological Reviews. 2006;209:10-27. 
 
 157 
99. Manley NR, Blackburn CC. A developmental look at thymus organogenesis: 
where do the non-hematopoietic cells in the thymus come from? Curr Opin Immunol. 
2003;15:225-32. 
100. Palmer DB, Viney JL, Ritter MA, Hayday AC, Owen MJ. Expression of the 
alpha beta T-cell receptor is necessary for the generation of the thymic medulla. Dev 
Immunol. 1993;3:175-9. 
101. Bendelac A, Matzinger P, Seder RA, Paul WE, Schwartz RH. Activation 
events during thymic selection. J Exp Med. 1992;175:731-42. 
102. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. 
STAT3 Mutations in the Hyper-IgE Syndrome. N Engl J Med. 2007;357:1608-19. 
103. Wright JT, Grange DK, Richter MK. Hypohidrotic Ectodermal Dysplasia. 
Gene Reviews. 2003. 
104. Itin PH, Fistarol SK. Ectodermal dysplasias. Am J Med Genet C Semin Med 
Genet. 2004;131C:45-51. 
105. Auricchio L, Adriani M, Frank J, Busiello R, Christiano A, Pignata C. Nail 
distrophy associated with a heterozygous mutation of the Nude/SCID human FOXN1 
(WHN) gene. Arch Dermatol. 2005;141:647-8. 
106. Pignata C, Fiore M, Guzzetta V, Castaldo A, Sebastio G, Porta F, et al. 
Congenital alopecia and nail dystrophy associated with severe functional T-cell 
immunodeficiency in two sibs. Am J Med Genet. 1996;65:167-70. 
107. Flanagan SP. 'Nude', a new hairless gene with pleiotropic effects in the 
mouse. Genet Res. 1966;8:295-309. 
108. Torfadottir H, Freysdottir J, Skaftadottir I, Haraldsson A, Sigfusson G, 
Ogmundsdottir HM. Evidence for extrathymic T cell maturation after thymectomy in 
infancy. Clin Exp Immunol. 2006;145:407-12. 
 
 158 
109. Nonaka S, Naito T, Chen H, Yamamoto M, Moro K, Kiyono H, et al. 
Intestinal gd T cells develop in mice lacking thymus, all lymphonodes, Peyer's 
patches, and isolated lymphoid follicles. J Immunol. 2005;174:1906-12. 
110. Iiai T, Watanabe H, Seki S, Sugiura K, Hirokawa K, Utsuyama M, et al. 
Ontogeny and development of extrathymic T cells in mouse liver. Immunology. 
1992;77:556-63. 
111. Sato K, Ohtsuka K, Hasegawa K, Yamagiwa S, Watanabe H, Asakura H, et 
al. Evidence for extrathymic generation of intermediate T cell receptor cells in the 
liver revealed in thymectomized, irradiated mice subjected to bone marrow 
transplantation. J Exp Med. 1995;182:759-67. 
112. Blais M, Louis I, Corneau S, Gerard G, Terra R, Perreault C. Extrathymic T-
lymphocyte development. Exp Hematol. 2003;31:349-54. 
113. Vigliano I, Gorrese M, Fusco A, Vitiello L, Amorosi S, Panico L, et al. 
FOXN1 mutation abrogates prenatal T-cell development in humans. J Med Genet. 
2011;48:413-6. 
114. Gunther U, Holloway JA, Gordon JG, Knight A, Chance V, Hanley NA, et al. 
Phenotypic characterization of CD3-7+ cells in developing human intestine and an 
analysis of their ability to differentiate into T cells. J Immunol. 2005;174:5414-22. 
115. Sanchez MJ, Gutierrez-Ramos JC, Fernandez E, Leonardo E, Lozano J, 
Martlnez-A. C, et al. Putative Prethymic T Cell Precursors within the Early Human 
Embryonic Liver: A Molecular and Functional Analysis. J Exp Med. 1993;177:19-
33. 
116. Haynes BF, Martin ME, Kay HH, Kurtzberg J. Early events in human T cell 
ontogeny. Phenotypic characterization and immunohistologic localization of T cell 
precursors in early human fetal tissues. J Exp Med. 1988;168:1061-80. 
 
 159 
117. Hayday A, Gibbons D. Brokering the peace: the origin of intestinal T cells. 
Mucosal Immunol. 2008;1:12-4. 
118. Kuo TC, Schlissel MS. Mechanisms controlling expression of the RAG locus 
during  lymphocyte development. Curr Opin Immunol. 2009;21:173-8. 
119. Oida T, Suzuki K, Nanno M, Kanamori Y, Saito H, Kubota E, et al. Role of 
Gut Cryptopatches in Early Extrathymic Maturation of Intestinal Intraepithelial T 
Cells. J Immunol. 2000;164:3616-26. 
120. Bruno L, Rocha B, von Boehmer H, Rodewald H-R. Intra- and extra-thymic 
expression of the pre-T cell receptor a gene. eur j immunol. 1995;25:1877-82. 
121. Bas A, Hammarstrom SG, Hammarstrom MLKC. Extrathymic TCR gene 
rearrangement in human small intestine: identification of new splice forms of 
recombination activating gene-1 mRNA with selective tissue expression. J Immunol. 
2003;171:3359-71. 
122. Uss E, Rowshani AT, Hooibrink B, Lardy NM, van Lier RAW, ten Berge 
IJM. CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J 
Immunol. 2006;177:2775-83. 
123. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal 
insufficiency and autoimmune polyendocrine syndromes: autoantibodies, 
autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 
2002;23:327-64. 
124. Kekalainen E, Tuovinen H, Joensuu J, Gylling M, Franssila R, Pontynen N, et 
al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy. J Immunol. 2007;178:1208-15. 
 
 160 
125. Buzi F, Badolato R, Mazza C, Giliani S, Notarangelo LD, Radetti G, et al. 
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time 
to review diagnostic criteria? J Clin Endocr Metab. 2003;88:3146-8. 
126. Peterson P, Peltonen L. Autoimmune polyendocrinopathy syndrome type 1 
(APS1) and AIRE gene: new views on molecular basis of autoimmunity. J 
Autoimmun. 2005;25:49-55. 
127. Randolph DA, Lewis DB. Transient deficiencies of T-cell-mediated 
immunity in the neonate. Adv Exp Med Biol. 2006;582:55-69. 
128. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ 
immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183-90. 
129. Picard C, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, et 
al. Primary Immunodeficiency Diseases: an Update on the Classification from the 
International Union of Immunological Societies Expert Committee for Primary 
Immunodeficiency 2015. Journal of Clinical Immunology. 2015;35(8):696-726. 
130. Van der Burg M, Gennery AR. The expanding clinical and immunological 
spectrum of severe combined immunodeficiency. Eur J Pediatr. 2011;170:561–71. 
131. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host 
defense: natural insights from evolutionary, epidemiological, and clinical genetics. 
Annu Rev Immunol. 2011;29:447-91. 
132. Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated 
cellular signaling pathways. Apoptosis. 2015;20(2):196-209. 
133. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic 
bacterial infections in humans with MyD88 deficiency. Science. 2008;321:691-6. 
 
 161 
134. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, P.D. A, et al. 
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. 
Medicine (Baltimore). 2010;89:403-25. 
135. Santolalla R, Abreu MT. Innate immunity in the small intestine. Curr Opin 
Gastroenterol. 2012;28:124-9. 
136. Novikova L, Czymmeck N, Deuretzacher A, Buck F, Richter K, Weber AN, 
et al. Cell death triggered by Yersina enterocolitica identifies processing of the 
proinflammatory signal adapter MyD88 as a general event in the execution of 
apoptosis. J Immunol. 2014;192:1209-19. 
137. von Bernuth H, Picard C, Puel A, Casanova JL. Experimental and natural 
infections in MyD88- and IRAK-4-deficient mice and humans. Eur J Immunol. 
2012;42:3126-35. 
138. Chou J, Ohsumi TK, Geha RS. Use of whole exome and genome sequencing 
in the identification of genetic causes of primary immunodeficiencies. Current 
Opinion in Allergy and Clinical Immunology. 2012;12(6):623-8. 
139. Yla-Anttila P, Vihinen H, Jokitalo E, Eskelinen EL. Monitoring autophagy by 
electron microscopy in Mammalian cells. Methods Enzymol. 2009;452:143-64. 
140. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 
2001;25:402-8. 
141. Saunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Alnadi NA, et al. 
Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive 
care units. Sci Transl Med. 2012;4:154ra35. 
 
 162 
142. Cirillo E, Giardino G, Gallo V, D'Assante R, Grasso F, Romano R, et al. 
Severe combined immunodeficiency—an update. Annals of the New York Academy 
of Sciences. 2015;1356(1):90-106. 
 
